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Preface 
Proteomics is the high-throughput characterization of the global complement of proteins in a 
biological system using cutting-edge technology (robotics and mass spectrometry) and 
bioinformatics tools ( Internet-based search engines and databases). 
In the early 1990s, the world of the protein biochemist was transformed by a series of 
technological development such as: new mass spectrometers (MS) , available bio-information 
and database containing protein and DNA sequences on the Internet, engines that enable MS 
data content to be rapidly compared with in silico versions to provide a protein identification. 
Now it is possible to analyze thousands of proteins with minimum sample preparation in 
automated high-throughput workflows. This revolution became known as proteomics which, 
in 1994, was defined by Marc Wilkins as “ the examination of a complete set of proteins 
synthesized by a cell under a given set of physiological or developmental conditions”1. 
Nowadays various range of proteomics strategies have evolved to answer specific problems. 
In particular, during my PhD studies, I focused my attention on the development and 
applications of proteomic approaches in two fundamental research areas.  
The first part of this thesis, is about proteomic applications in drug discovery (chemical 
proteomics). It is a useful tool to identify the target of a new class of antimalarial compounds 
that I have synthesized during my undergraduate thesis. Chemical proteomics is a currently 
emerging field with the mission to identify and validate target protein that directly binds with 
a binder such as a bioactive small molecule in a rapid, systematic and comprehensive manner 
by design, synthesis and application of relevant chemical probes. As a multidisciplinary 
science, chemical proteomics proposes the integration of tools and technologies from a variety 
of disciplines (chemistry, biochemistry, biology, proteomics and informatics). Thus, an 
integrated strategy in chemical proteomics can provide the information about the binding site 
of a bioactive small molecule in its target protein and, importantly, it could be the starting 
point to develop the drug screening system based on the structure of target protein2.  
The second part of this thesis, is about proteomic approach in biomarker discovery that could 
be an useful tool for biomarker identification, that can be used as measurements within 
clinical studies and for the purpose of predictive diagnosis. In particular the aim of my 
research will be the detection and quantization of post-translational modifications of proteins 
caused by oxidative and carbonyl stress. While the development of specific antibodies against 
modified proteins has made possible to confirm the occurrence of oxidative stress in vivo and 
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its involvement in several physio-pathological conditions, the resultant chemical 
modifications of proteins has not yet been explored. Hence we need proteomic tools, which 
can sensitively detect oxidative damage on peptides and proteins: these tools would be helpful 
to understand exactly when, how, and where the damage occurred, and to explore the 
mechanism of onset, progression, and/or complications of the diseases.
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1. Introduction 
1.1 Malaria 
Malaria has a massive impact on human health, being one of the major disease in the world 
causing in 2010 approximately 655,000 deaths3.  
It is an infectious disease caused by the protozoa of the genus Plasmodium. There are at least 
150 species of malarial plasmodia which parasitize vertebrate hosts, such as reptiles, birds, 
primates and humans, but every kind with his own specific parasite. The species of 
Plasmodium which cause malaria in humans are four: P. vivax, P. ovale, P. malariae and P. 
falciparum. 
It is estimated that every year 243 millions of people have been affected by this disease, with 
93% of cases due to P. falciparum, the agent that causes the most severe form of malaria4. 
In recent years, the progress made to fight the spread of malaria has been remarkable, 
especially through the use of mosquito nets and new treatments, despite that about half of the 
global population risks the infection. Moreover in 108 countries the disease is endemic 
(Figure 1)4. 
 
 
 
Figure 1: Countries where malaria is endemic under control, pre-elimination, elimination and prevention      
against reintroduction. 
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According to the World Health Organization’s data, 91% of the deaths due to malaria 
involved the regions of Africa (particularly sub-Saharan Africa), where the most affected 
people were children under 5 years and pregnant women3.  
Although malaria is the first cause of death in Africa, also Asia, (limited to West Asia and 
Middle East) and Latin America are considered high-risk areas5. 
Malaria has been defeated in many countries as United States of America and European 
Union, but even in these areas are reported cases related mainly to immigrants or tourists 
coming back from infection risk areas4. 
The geographical distribution of the disease is linked to climatic factors such as temperature, 
humidity and rain, in fact the ideal places for mosquito breeding are the tropical and 
subtropical regions. 
Malaria is considered one of the "poverty diseases" because it shows epidemiology associated 
with poor economic, social and health conditions typical of the countries in development. The 
population at risk of malaria infection lives in the poorest countries of the planet, where the 
annual per capita income is less than $ 400 USA6.  
The disease is also a real cause of impoverishment: in countries with high transmission, 
malaria causes an average loss of 1,3% economic annual growth 7. Over time, this loss leads 
to substantial differences between the PIL of the countries in which malaria is endemic and 
those where it has been defeated7. 
The direct costs of malaria include public and private spending for prevention and treatment 
of the disease. In some countries, malaria is the cause of 40% of public health expenditure, 
39-50% of hospital admissions and 60% of day care consults. 
In the most affected regions, the infection has a direct impact on human resources because 
hinders social development and decreases school attendance and so the learning attitude4. The 
majority of imported malaria cases are reported in the European Union, in particular in 
France, the United Kingdom, Germany and Italy. Every year between 10,000 and 12,000 
cases of imported malaria are reported4. 
For over 50 years alkaloids of cinchona and their derivatives have been used to control 
malaria. Chloroquine has been one of the most effective anti-malarial drugs ever produced. 
However, resistance to chloroquine by Plasmodium falciparum was manifested for the first 
time in South East Asia and South America, and now has spread to Africa and Asia. This has 
led to a global resurgence of malaria. 
Currently these alkaloids are replaced by terpene Artemisia Annua. 
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The Artemisinin, a very effective antimalarial and expensive compound, quickly became the 
first drug to be used when other therapeutic approaches were unsuccessful. Unfortunately, in 
some regions, the parasite is developing resistance even against Artemisinin8. 
Therefore, there is a huge need to develop new antimalarial agents that, compared to 
traditional drugs, will be active against these resistant strains with improved pharmacokinetic 
properties, fewer side effects and lower costs. 
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1.2 Life cycle of the parasite 
Malaria is usually transmitted from person to person almost exclusively by a female mosquito 
of the genus Anopheles, while there are rare cases of accidental transmission due to blood 
transfusions or use of contaminated syringes. 
 
Figure 2: Plasmodium life cycle  
 
The infected mosquito transmits malaria to everyone who can bite during its life cycle, 
inoculating, along with saliva, the infectious forms of the parasite named sporozoites. The 
sporozoites remain in circulation for less than half an hour, then move into the liver, in the  
parenchymal cells. This phase is called "hepatic phase". During this phase the sporozoites 
undergo a first cycle of asexual multiplication with the production of plurinuclear schizonts 
which are divided into many intracellular mononuclear merozoites. After that the infected 
hepatocytes break and release merozoites into the blood stream. The merozoites stick together  
to the red blood cell membrane starting a new phase called "red cell cycle", the second 
asexual cycle. The merozoite turn in trophozoite and it is recognizable under the microscope 
due to typical ring shape of the trophozoite. The trophozoites initially grow feeding on the 
hemoglobin, then split up itself and reach the stage of schizont. After a series of nuclear 
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divisions, the erythrocytes are broken and release numerous merozoites (from 6 to 36 per 
schizont) which start a new invasion cycle in other red blood cells. 
The symptoms of malaria are characterized by febrile (coinciding with the breakdown of red 
blood cells and the subsequent invasion of new erythrocytes), chills, splenomegaly and 
anemia. 
Depending on the plasmodium kind infecting, the cycle repeats at regular intervals: in cases of 
P. falciparum (malignant tertian malaria), P. ovale and P. vivax (benign tertian malaria) every 
48 hours, while in the case of P. malariae (malaria quart) every 72 hours. The destruction of 
the red blood cells causes anemia, while their aggregation and adhesion in several vital organs 
microvasculature leads to a blockage of blood vessels, causing a decrease of oxygenation of 
organs such as liver, kidneys or, in the case of P. falciparum, brain (cerebral malaria), causing 
the death7. 
In P. vivax and P. ovale hepatic parasites persist in the form of hypnozoites to generate, after 
months or years, new infections of red blood cells, known as "malarial relapse." 
Some trophozoites transform into male and female gametocytes (erythrocyte gendered forms). 
When a mosquito bites an infected person, ingests these sexual forms that, in the stomach 
mate (cycle "sexed" or "sporogonic") to produce numerous oocyst. The oocyst become 
sporozoites and accumulate in the salivary glands of the vector. When the Anopheles 
mosquito bites a new individual, it is capable of transmitting malaria to the subject. 
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1.3 Pathogenesis 
The growth of the parasite causes significative changes in the host red blood cell (RBC), that 
have been studied for many years and are the most apparent cause of pathogenic events. On 
the erythrocyte membrane there are protuberances called "Knobs", consisting in specific 
proteins of the parasite (HRP-"histidin rich protein"), and red blood cell that mediate adhesion 
of parasitized RBCs on vascular endothelium causing the formation of so-called "rosettes" 
(aggregates composed by a parasitized red blood cell surrounded by RBC not parasitized and 
4-hydroxynonenal [4-HNE]) 9. The phenomenon of adhesion and occlusion of capillaries 
together with the high production of inflammatory factors, such as NO and TNF, is 
responsible of tissue damage, hypoxia and metabolic acidosis that characterize cerebral 
malaria and cause seizures, coma and death10. 
Anemia, that can be established in cases of severe malaria (SMA), is a frequent complication 
of malaria caused by P. falciparum due to the loss of parasitized or not parasitized 
erythrocytes and erythropoiesis inhibition11. 
The RBC loss is a process not yet fully understood and may be affected by the formation of 
rosettes. 
The inhibition of erythropoiesis can be characterized by: a reduction of the number of 
circulating reticulocytes, a normal or increased production of erythropoietin (EPO) and the 
altered morphology of erythroid precursors12, 13. 
The erythropoiesis takes place in the eritroblaste islands that have inside a macrophage which 
supplies iron, cytokines, chemokines and grow factors to the erythroblasts that surround it14. 
The analysis of the bone marrow (BM) of individuals died for anemia caused by severe 
malaria, showed that macrophages of eritroblaste islands contain the malarial pigment called 
hemozoin (HZ), that derives from the crystallization of heme molecules (β-hematin) together 
with a substantial amount of polyunsaturated fatty acids (such as arachidonic acid), which are 
not enzymatically peroxidized and split up to form the complex HZ-Fe and the terminal 
hydroxyaldehyde such as 4-hydroxynonenal (4-HNE) 15. 
It has been observed that there is a relationship between the large number of BM macrophages 
loaded of hemozoin, the morphological abnormalities of the RBC, the reduction of 
reticulocytes and the severity of malaria. 
HNE is a highly bioactive molecule able to bind covalently with nucleophilic portions of 
macromolecules such as proteins and DNA, generating cell damage and subsequent death due 
to necrosis and apoptosis. 
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Recently it has been demonstrated that monocytes containing hemozoin inhibit the growth of 
surrounding erythroid cells and produce HNE that, spreading to adjacent cells, generates 
protein adducts able to interact with the cell cycle without causing apoptosis, in particular by 
modifying the proteins p53 and p2115. 
Furthermore, hemozoin and HNE are able to inhibit the expression of certain key proteins of 
normal erythropoiesis, such as transferrin receptors, interleukin-3 and erythropoietin16. 
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1.4 Degradation of hemoglobin 
 
The degradation of human hemoglobin is one of the metabolic processes essential for 
parasite’s survival. In the intraerythrocytic phase of its life cycle, the merozoite reproduces 
itself asexually in red blood cells, requiring a significant amount of nutrients to survive and to 
proliferate17. The parasite does not possess the ability to synthesize amino acids de novo, thus 
the host hemoglobin’s catabolism becomes the main source of amino acids. The parasite uses 
these mechanisms not only for protein synthesis, but also to ballast the intracellular 
osmolarity during its replication and its development into erythrocytes18;19. 
Inside the parasite digestive vacuole, a lysosomal specialized organelle which presents a pH 
between 5.2 and 5.620, occurs the hemoglobin degradation process. Many proteolityc 
enzymes21 are involved in the degradation process, including aspartic proteases (plasmepsin), 
cysteinic proteases (falcipain), metallo proteases (falcilysine), a dipeptidyl aminopeptidase1 
(DPAT1) and histo-aspartic protease (HAP) 22,23 (Figure 3). 
Studies show that Plasmepsins (Plm I; Plm II)  perform the first cleavage of hemoglobin 
between Phe33-Leu34 producing large peptide fragments. These fragments are then cut by a 
cysteinic protease called falcipain. Falcilisine and DPAP1 degrade these new peptides into 
smaller fragments which are subsequently hydrolyzed to amino acids by aminopeptidase. 
During the degradation of hemoglobin, the heme is released [Fe (II)] and is oxidized to 
hematin [Fe (III)]. 
In mammals, the hematin is degraded by the heme oxygenase/reductase and the biliverdin. 
The malaria parasite has developed its own way of hematin detoxification by the conversion 
into a black substance, insoluble and crystalline, known as "malaria pigment" or hemozoin. It 
has been shown that at least 95% of the heme released from hemoglobin is converted into 
hemozoin. 
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Figure 3: Hemoglobin degradation 
 
Plasmepsin 
 
Into the P. falciparum digestive vacuole have been identified 3 different aspartic proteases: 
the plasmepsin I (Plm I), the plasmepsin II (Plm II) and the plasmepsin IV (PlmIV) and a 
histo-aspartic protease (HAP), which are all involved in the degradation of hemoglobin. The 
four plasmepsins are highly homologous to each other, sharing more than 60% amino acid 
identity. On the contrary HAP is unique in its kind, because it has histidine in place of the first 
canonical aspartic acid, but it is still an active protease that may function like an aspartic or 
serine protease mechanism17. 
It has been proved in vitro the importance of aspartic proteases during the erythrocytic stage: 
inhibiting these enzymes with plasmepsin inhibitors, the parasite growth can be blocked. 
Observing the growth of plasmodia knock-out for plasmepsin genes, either in culture rich of 
nutrient or with a limited availability of amino acids, was detected a decrease in parasites 
growth17. 
Thanks to these observations, plasmepsins are considered interesting targets, suitable for the 
development of drugs able to overcome the problem of resistance. The research focused 
mainly on the identification of new plasmepsin II inhibitors, because the enzyme can be 
produced in large quantities by E. coli and, after purification, reported in enzymatically active 
conformation. 
Each plasmepsin has a different cleavage specificity and it demonstrates the existence of a 
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synergistic mechanism17. So the use of selective agents is restricted, requiring the 
development of inhibitors active against each one of the four plasmepsins24. 
A different approach could be to obtain inhibitors of the enzyme responsible for the 
maturation of the pro-plasmepsin. As matter of fact recent studies demonstrated that only one 
enzyme is responsible for the cleavage of all pro-plasmepsins17. 
 
Falcipain 
 
Using inhibitors of proteases cysteinic, such as Leupetina and E-6425;26, it has been 
demonstrated that these proteases have a fundamental role in the hemoglobin degradation, 
because their inhibition causes the block of the catabolic process. 
The most studied family of cysteine proteases in P. falciparum is falcipain. The genomic 
sequence shows that there are four types of falcipain: falcipain-1, falcipain-2, falcipain-2 ' and 
falcipain-3. There is little homology between the falcipain-1 gene and the other three 
falcipaines (about 40%), while falcipaine-2 and 3 have a sequence much more similar (about 
80%). 
Recently falcipain-2 has been isolated and it has been demonstrated that it is responsible for 
more than 90% of the activity of proteases cysteinic identified in the trophozoites lysate27. 
Every falcipain is expressed at different stages of the parasite life cycle, in fact falcipain-2 and 
falcipain-3 are expressed into the trophozoite stage, while falcipain-1 is expressed into the 
merozoite stage28. 
Falcipain-2, being able to hydrolyse the proteins of the cytoskeleton of erythrocyte, is 
necessary for the release of merozoites that rapidly invade other red blood cells to repeat the 
asexual cycle. It has been demonstrated that the inhibition of protease cysteineynic involves 
the failure of the erythrocyte lysis, which completes the erythrocytic cycle of Plasmodium. 
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1.5 Antimalarial therapy 
 
The first active drug used for the treatment of malaria was the bark of the Cinchona plant, 
discovered in Perù in 1600 and imported to Europe by the Jesuits. In 1800 in France, chemists 
Pelletier and Caventou isolated in pure form quinine from the Cinchona bark. The Dutch 
cultivated Cinchona ledgeriana in large plantations in their colonies in Indonesia. The bark of 
Cinchona alkaloids contains other anti-malarial drugs (quinidine, cinchonine, cinchonidine) 
but the most used was quinine. For centuries, despite of its side effects, quinine remained the 
only anti-malarial drug used. During the World War I, the blockade of ports and submarine 
attacks hindered the supply of quinine, so it was necessary to synthesize new antimalarial 
drugs, such as pamaquine, primaquine and mepacrine. The need to protect the American 
troops in the Pacific during the World War II, encouraged the development of new 
antimalarial drugs. In fact after World War II it has been discovered chloroquine, 
amodiaquine, pyrimethamine and proguanil (used for prophylaxis).  
As chloroquine resistance appeared in South America and South East Asia in 1960, 
associations of sulfonamide with pyrimethamine and quinine with tetracycline were then 
used. During the Vietnam War at the U.S. Army Research Institute "Walter Reed" was 
discovered mefloquine, but unfortunately mefloquine resistance appeared soon in Thailand. 
Thus was observed that in traditional Chinese medicine for many years was used an extract of 
Artemisia annua for the treatment of fevers. So in 1971 it was extracted from this plant 
artemisinin, a drug with no resemblance to the previous antimalarials, and were subsequently 
synthesized the artemether, artesunate and arteetere. Currently there are continuous studies in 
order to discover and synthesize antimalarial drugs more effective and safe. 
The set of compounds is shown in Table 1.1 In the second half of the 20th century, the most 
used drug for the treatment of malaria was chloroquine (CQ). In recent years, the widespread 
and indiscriminate use of all antimalarials has prompted the development of parasites with 
high levels of resistance to all classes of drugs.  
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Table 1.1 
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1.6 Action mechanism of the main antimalarial agents 
 
Chloroquine 
 
A selective accumulation of chloroquine was observed in the digestive vacuole of the parasite, 
where the degradation of the hemoglobin takes place. 
 
 
 
The weak basic properties of chloroquine can explain this accumulation: at neutral pH 
chloroquine diffuses easily through the membranes as free base, but at the acidic pH of the 
digestive vacuole chloroquine is protonated and can no longer diffuse outwards. The 
chloroquine prevents the polymerization of hematin (H2O/HO-Fe (III) PPIX) to hemozoin or 
β-hematin ([Fe (III) PPIX] 2) through the formation of an adduct π − π with the hematin that 
is toxic for the plasmodium. The toxicity of this complex leads to oxidative stress due to the 
peroxidation of membrane lipids of the parasite and subsequent death of the parassite. 
 
Artemisinin 
 
Artemisinin is an endoperoxide sesquiterpene isolated from Artemisia Annua which is 
characterized by a high activity against P. falciparum. 
The compound was already known and well documented in medical treatises such as the 
"Compendium of Materia Medica" written in 159629. 
The dihydroartemisinin is an antimalarial compound characterized by a seven times higher  
activity against Plasmodium that has been obtained by the reduction of artemisinin30. 
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                        Artemisinin  IC50: 13 nM (D10); 9nM (W2)                Dihydroartemisinin 
 
Changing the lactone system it has been developed the first generation of artemisinin, 
including artemeter31, arteeter32, 33 and artesunate34, 35. 
 
 
                                    Artemeter                           Arteeter                         Na Artesunate  
Artemeter and arteeter are lipophilic compounds and have a higher intramuscular 
bioavailability, while the artesunate is soluble in water and generally is administered 
intravenously. These analogs are safe, able to rapidly reach active blood concentrations and  
active towards the P. falciparum. They are generally administered in combination with a long-
term antimalarial drug36. 
The mechanism of artemisinin has not been clarified yet, but it could be due to an interaction 
of the molecule endoperoxydase function with the heme group (resulting in the degradation of 
hemoglobin), followed by the formation of free radicals capable of alkylating various 
biological targets37,38. 
 
The possible presence of multiple targets can explain the delay in the resistance diffusion. 
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Atovaquone 
 
Atovaquone is a derivative hydroxy-1,4-naftochinonico, that is a highly lipophilic molecule, 
with a very low water solubility and high metabolic stability. 
Usually is associated with proguanil (Malarone) against chloroquine-resistant strains of 
Plasmodium, while the resistance against P. falciparum rapidly occurs if used alone39. 
 
Atovaquone  IC50: 0.3 nM (D10); 0.43 nM (W2)                            Ubiquinone 
 
Atovaquone is characterized by a mechanism that could explain why its resistance may arise 
quickly in malaria parasites40. The drug acts by inhibiting mitochondrial electron transport at 
the level of cytochrome bc1 complex in malaria parasites at 100-fold lower concentrations 
than effective for the mammalian mitochondria. In fact, this molecule has a similar structure 
to ubiquinone (also called coenzyme Q), an essential component of the electron flow in the 
aerobic respiration; ubiquinone accepts electrons from the enzyme dehydrogenase and 
donates them to cytochromes involved in the electronic transport chain40;41. The passage of 
electrons from ubiquinone to cytochrome bc1 (complex III) requires binding of coenzyme Q 
complex III at the Qo cytochrome domain; this step is inhibited by atovaquone. The structure 
of the Qo cytochrome binding site has been defined and explains the selective toxicity of 
atovaquone to parasitic mitochondria40;42. 
Several parasite enzymes are linked to the mitochondrial electron transport system and are 
inhibited. Among these enzymes, there is the dihydroorotate dehydrogenase (DHOD), which 
is required in the biosynthesis of pyrimidines. As plasmodia is unable to scavenge 
pyrimidines for DNA synthesis and it is required to synthesize them de novo, inhibition of 
DHOD results in parasite death40;43. 
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1.7 Combination therapy 
 
Since parasites developed resistance to most of the existing drugs, it is considered a new 
therapeutic strategy to fight morbility and mortality due to infection by P. falciparum: the 
combination of two or more antimalarial drugs against different targets, with additive or 
synergistic action. The ultimate goal is the effective elimination of the parasite in the shortest 
time, considering that two drugs in combination may have different characteristics. 
The half-life is an important parameter to be considered, in fact if the component with a low 
half-life can eliminate most of the parasites (such as artemisinin and its derivatives) and have 
a short effect, the second compound, with a long half-life (eg. mefloquine and lumefantrine) is 
able to eliminate few parasites, should have a low risk of developing resistance44. 
Although the combination sulfadoxine-pyrimethamine is excellent and has good activity 
against P. falciparum, the long half-life of the active ingredients involves the development of 
resistance, especially in areas of high transmission, such as in eastern Africa44. 
Studies demonstrated that the synergistic interaction between atovaquone and proguanil 
(Malarone), is also active against P. falciparum chloroquine resistant strains. 
The association between cicloproguanile and dapsone (Lapdap) is another combination used 
in clinical study. 
The artemisinin and its analogues are frequently used in combination therapy due to their  
excellent chemical-physical properties like rapid-action, short half-life, limited toxicity, 
activity towards multi-drug resistant strains. 
Artemeter and lumefantrine in combination (Coartem) are effective against P. falciparum 
multidrug resistance and present no serious side effects. Other interesting combinations are 
artesunate (similar to artemisinin), with mefloquine, sulfadoxine-pyrimethamine or dapson-
cloroproguanile36;45. However in 2006, it has been reported the first case of resistance to 
artemisinin on the border between Thailand and Cambodia46. 
In 2011, the European Medicines Agency has approved Eurartisim, association of 
Diidroartemisin-piperaquine, developed by Italian Sigma-Tau in collaboration with Medicines 
for Malaria Venture. 
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1.8 Resistance 
 
The number of deaths caused by malaria have increased due to the resistance of P. falciparum 
against quinolines and in particular chloroquine 47. The areas characterized by the presence of 
parasites resistant to chloroquine or mefloquine are represented in Figure 4. 
 
 
Figure 4: Zone of resistance 
 
Chloroquine resistance is associated with the reduction of its accumulation inside the 
digestive vacuole47. 
Both genetic and biochemical studies have attempted to explain why parasites become 
resistant to chloroquine. 
These theories include: 
¾ the alteration of the Na+/H+ pump which causes an increase of the cytoplasmic pH and 
a reduction of the uptake of chloroquine48; 
¾ the gene Pfmdr amplification that involves overexpression of the protein Pgh-1, 
causing the drug loss; 
¾ digestive vacuole membrane mutations: P. falciparum cloroquine resistance 
transporter (PfCRT). 
However only the mutation of Pgh-1It is not enough to confer resistance to the parasite but 
other mutations are necessary. 
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Rowena E. Martin et al. in their recent studies showed the correlation between the PfCRT 
mutations and the chloroquine resistance49. This protein is localized in the digestive vacuole 
membrane and has 10 transmembrane domains. 
When the mutation of this protein occurs, in particular at Lys76 and Thr (K76T), it causes the 
modification of the first transmembrane domain and significant increase of chloroquine 
resistance is observed. Reed et al. have shown that the mutation of the protein Pgh-1 
contributes not only to the chloroquine resistance but also to a modulation of the resistance to 
other compounds such as mefloquine, alonfantrine and quinine50. 
Compounds strictly analogous to chloroquine are active on chloroquine-resistant strains, thus 
demonstrating that the resistance is not attributable to target changes, but is compound-
specific. 
Therefore, the chloroquine resistance can be overcome, realizing compounds able to act on 
drug outgo protein, or developing quinoline derivatives, agents with the same mechanism of 
chloroquine, which are not recognized by the transport protein.  
Mitochondrial DNA (mtDNA), with 6 kb of length, is quite unusual in malaria parasites and 
is the shortest mtDNA known40;51; it is also highly conserved. It encodes for only three 
proteins (subunits I and II of cytochrome oxidase c and cytochrome b). 
It has been observed that the resistance to various cytochrome bc1 complex inhibitors is 
characterized by mutations in a defined region coding for the cytochrome b sequence and 
diversity in these positions may concern the different toxicity of antimalarial 
idroxyinaftoquinonic40;51. 
The region of the cytochrome b implicated in the mechanism of resistance is part of the 
catalytic domain, the site Qo, in which ubiquinol is oxidized by the complex bc; in particular, 
the mutations observed in P. yoelii resistant covers a region of 15 amino acids surrounding the 
highly conserved sequence of the cytochrome PEWY B40;41;52. Mutations alter the 
hydrophobicity and the volume of the part of the binding cavity: therefore even slight 
variations can affect the affinity of atovaquone towards cytochrome bc140. The resistance to 
atovaquone rapidly onset in malaria by P. falciparum when it is used as a single agent and 
experimental evidence have shown that parasites that become resistant to atovaquone are also 
resistant to the synergistic effects of proguanil, thus making the association weak40. 
Even combinations of two or more drugs may present resistance, especially combinations 
with long half-life drugs such as sulfadoxine and pyrimethamine. 
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1.9 Resistance to Artemisinin 
 
Combination therapy based on derivatives of artemisinin or ACT (artemisinin combination 
therapy) provides an important alternative to quinoline derivatives. 
The resistance to quinoline compounds has emerged on the border between Thailand and 
Cambodia and later spread worldwide. This has seriously affected their employment and has 
contributed to a dramatic increase in mortality due to malaria before the introduction of ACTs 
at the end of the last century53. 
In the last decade almost all countries with endemic malaria have adopted a combination 
therapy of artemisinin derivatives for the treatment of P. falciparum malaria. The artemisinin 
has a very short half-life and is rapidly eliminated from the body due to glucuronidation by 
CYP 2B68. For this reason, this molecule is usually associated with long half-life antimalarial 
drugs such as piperaquine and amodiaquine8. In 2006 was registered the first case of 
resistance to artemisinin in Ta Sanhal, a small city near the border between Thailand and 
Cambodia. 
The cause of resistance to artemisinin in South-East Asia has been assigned to the widespread 
use of this drug in monotherapy53. 
The 'World Health Organization' (WHO), even before the artemisinin resistance has been 
reported, banned artemisinin monotherapy to delay the development of resistance and protect 
these important derivatives for antimalarial therapy.  
Although Vietnam has been the country that used artemisinin monotherapy in South East Asia 
for the longest time, surprisingly it was not the first country to develop resistance. 
In fact, in Vietnam, artemisinin is used to control malaria since 1989, and although current 
national guidelines recommend to use ACT, artemisinin and artesunate monotherapy are still 
widely available through the private sector (pharmacies and shops). Vietnam is also one of the 
few countries where artemisinin monotherapy leaded to a highly successful program for the 
malaria control.  
The cases of malaria in the country fell sharply from 1,672,000 with 4,650 deaths in 1991, 
91,635 clinical cases with 43 deaths in 200653. 
Current data suggest that resistance to artemisinin is simply a natural consequence of the 
massive use of ACTs in South East Asia46. 
Since when the resistance to artemisinin has been observed for the first time in 2006, the 
WHO started an ambitious campaign to contain the problem of resistance along the border 
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between Thailand and Cambodia. These efforts included detection and early treatment of all 
malarial infections on both borders, preferably with a therapy that is not based on ACTs. 
Thus follows the distribution of insecticide-treated nets to reduce malaria transmission and a 
more detailed mapping of the spread of resistance to artemisinin. 
History teaches us that the border between Thailand and Cambodia has always been a hot spot 
for the development of resistance to antimalarial drugs and that it can emerge independently 
in other parts of the world53. 
The possibility that the parasite can develop resistance to artemisinins could be a catastrophe 
for overall health, because currently there are no drugs that can replace artemisinin, and it 
may take five or more years to find drugs equally effective and safe8. 
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1.10 Chemical proteomics 
 
Chemical proteomics is a currently emerging field with the mission to identify and validate 
target protein that directly links with a binder such as a bioactive small molecule in a rapid, 
systematic and comprehensive manner by design, synthesis and application of relevant 
chemical probes. As a multidisciplinary science, chemical proteomics proposes the integration 
of tools and technologies from a variety of disciplines (chemistry, biochemistry, biology, 
proteomics and informatics). Thus, an integrated strategy in chemical proteomics can provide 
the information about the binding site of a bioactive small molecule in its target protein and, 
importantly, it could be the starting point to develop the drug screening system based on the 
structure of target protein2.  
Chemical proteomics comes in two different methods: (i) activity based probe profiling 
(ABPP), which focuses on the enzymatic activity of a particular protein family, and (ii) a 
compound-centric approach, which focuses on characterizing the molecular mechanism of 
action of an individual bioactive small molecule. Thus, they also serve different purposes. 
ABPP detects members of a defined class of enzymes that are active under certain conditions 
for example, in a disease. This method can lead to the identification of new proteins with the 
respective biochemical activity, or it can be applied to determine the selectivity profile of 
drugs targeting an enzyme family via pretreatment of the lysate with the drug of interest and 
subsequent labeling and identification of the remaining enzymes using appropriate reactive 
probes.  
Compound-centric chemical proteomics consists of classical drug affinity chromatography 
that is similar to the method used for decades but that is now performed in combination with 
modern high-resolution mass spectrometry (MS) analysis and statistics or bioinformatics for 
subsequent identification of binding proteins. This approach benefits from the tremendous 
technological developments in the MS field during recent years, particularly with regard 
to sensitivity and throughput. The development of nano-electrospray ionization (ESI) and 
methods for quantification such as stable isotope labeling and the analysis of important post-
translational modifications (for example, phosphorylation) were major breakthroughs and 
deserve special mention in this context. The emergence of highly sensitive, high-resolution 
instrumentation such as quadrupole time-of-flight or linear ion trap (LTQ)/Fourier transform 
ion cyclotron resonance (FT-ICR) and LTQ/orbitrap mass spectrometers has opened up new 
possibilities. It is important to note that the technology requires access to purpose-fitted 
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laboratory information management systems, statistical evaluation and database management 
necessities that are not to be underestimated by those considering adopting the technology. 
A typical chemical proteomics experiment (Figure 5) starts with immobilizing a bioactive 
compound on a matrix, such as sepharose or agarose.  
 
 
Figura 5: Chemical proteomic approach 
There are various commercially available activated resins that allow for the attachment of 
specific chemical groups (for example, sulfhydryl, amino, hydroxyl or carboxyl groups). 
When a compound needs to be modified for immobilization, it is important to follow up this 
modification chemistry with an appropriate biochemical or cell-based assay to ensure that 
activity is retained.  
In parallel, a cell extract is prepared either from cells or tissue. Subsequently, this lysate is 
incubated with the affinity matrix and washed extensively before elution. Depending on the 
experimental strategy, washes of different stringencies are used. Detergents, salts or 
denaturing agents can be used for nonspecific elution. More specific elution can be achieved 
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by competition with an excess of soluble compound or via specific cleavage of an engineered 
linker. 
Processing by SDS-PAGE (one- or two-dimensional) or a gel-free method (‘shotgun 
proteomics’) and subsequent digest of the proteins with a protease, typically trypsin, generates 
a complex peptide mixture that is then analyzed by nano-HPLC coupled to nano-ESI-MS/MS. 
The results are searched against an appropriate protein database (for example, SwissProt or 
the US National Center for Biotechnology Information) with a search engine (for example, 
Mascot or Sequest) before being submitted to a more in-depth bioinformatic analysis. 
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2. Purpose of research 
 
Currently about 40% of the world population is at risk of malaria infection. 90% of malaria 
deaths occur in sub Saharian regions4. The WHO estimates that the clinical cases of malaria 
are 300/500 millions every year, with more than one million deaths every 10 seconds. There 
are many children that, suffering from an acute attack of malaria, undergoes to a cerebral 
form, with coma and fatal outcome. In Africa, malaria causes 20% of infant mortality, 30-
50% of outpatient visits and 50% of admissions. In endemic areas, pregnant women are four 
times more susceptible to malaria attacks4. 
Malaria mainly affects the poorest people of the World, but the low-cost drugs available, such 
as chloroquine, are those for which the parasite has developed resistance. In addition, in some 
regions of South East Asia, the phenomenon is spreading towards more effective therapies 
based on the use of artemisinin derivatives54. Therefore it is necessary to discover new 
antimalarial agents that present low cost and capability to overcome the resistance problem, 
acting on new targets. 
In the digestive vacuole of P. falciparum there are plasmepsines I, II and IV and an hysto 
aspartic protease that are involved in the hemoglobin degradation cascade, an essential 
process for the Plasmodium survival19. Therefore they represent a very promising target for 
the design of new antimalarial agents. However, it is known that the four proteases have 
acquired complementary roles that increase their catalytic efficiencies. Recent studies have 
demonstrated that parasites stay alive even if they have lost one or two enzymes as a result of 
a genic deletion17. Therefore it is necessary to develop non-specific inhibitors of plasmepsins. 
This may explain why the molecules synthesized shown little effect on the growth of P. 
falciparum even if they inhibit plasmepsins at nanomolar range.  
The Professor Romeo’s laboratory has obtained interesting results55 by applying the approach 
called "double drugs". It consists in the synthesis of a compound characterized by the 
presence of two molecules able to interact with two different drug targets. This molecules are 
linked through a binder.  
In particular have been synthesized compounds that may present antimalarial activity, 
characterized by a β-hydroxy-γ-amino acid (statin), as a potent inhibitor of nonspecific 
plasmepsine, primaquine, atovaquone or the 4-amminoquinolinic core, characteristic of 
chloroquine. The statin acts by mimicking the tetrahedral intermediate transition which is 
formed during the hydrolysis of the peptide bond by the plasmepsine.  
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Statine 
The most active compound of each series are shown in Table 2.1. 
 
  
D10 
IC50 
(nM) 
W2 
IC50 
(nM) 
RV97 
 
400 700 
PM47 
 
4.8 5.3 
FP37 
 
114.2 63.7 
 
Table 2.1 
 
RV97 belongs to the first series synthesized and it is characterized by a dipeptide linked to 
primaquine, 4,4'-oxybisbenzoic acid, an aromatic linker optimized from a previous study, and 
the statin containing the dipeptide Ile-Leu functionalized with the butilammide. The 
primaquine is one liver schizonticide and therefore does not interfere with the statin 
mechanism of action. Recently it has been demonstrated that the serious side effects due to 
primaquine can be reduced by binding the drug to a peptidic component56. The quinolinic 
structure acts as a carrier of the "double drugs" because it promotes the membrane cross. The 
compound inhibits the growth of P. falciparum at the intraheritrocitic stage on both 
chloroquine-sensitive strains (D10) and chloroquine-resistant strains (W2). 
It showed a good in vivo activity (ED50 = 6.11 mg/Kg) comparable to that of chloroquine and 
a good plasmepsine I, II and IV inhibition (Plm I: 110 nM; Plm II: 0.4 nM; Plm IV: 0.5 nM). 
H2N
OH
OOH
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The development of the “double drugs” continued with the replacement of primaquine with a 
prodrug of atovaquone, described in earlier studies,57 characterized by a carbamate, allowing 
the improvement of solubility in water and the increas release of atovaquone with a pH-
dipendent mechanism 58. PM47 presents a good P. falciparum growth inhibitory activity in 
vitro (IC50 = 5.3 nM) against plasmodia chloroquine resistant strains (W2). 
Considering the promising results obtained with the approach called "double drugs", it has 
been designed a series of inhibitors using a new pharmacophore: the 4-amminoquinolinic 
core, characteristic of chloroquine.  
The chloroquine combined with an inhibitor of Plasmepsine, should not lead to an 
improvement of the P. falciparum growth inhibitory activity because the heme group, 
obtained from the hydrolysis of hemoglobin by plasmepsins, is essential for the 
pharmacological action of chloroquine. Recent studies have demonstrated that plasmepsins 
are not the unique enzymes family capable to cleavage hemoglobin, but in the digestive 
vacuole there are other proteases with same function: the falcipain. Therefore it is possible 
that, despite the plasmepsine are effectively inhibited, there could be a constant heme group 
release. Thus the presence of chloroquine, combined with the statin in the same molecule, 
could lead to a marked improvement of the P . falciparum growth inhibitory activity. 
Different 4-amminoquinolinic derivatives have been synthesized. They are characterized by 
the 4-amminoquinolinic system linked to 4,4'-oxybisbenzoic acid as linker using different 
spacer containing amino acids or not. 
FP37 was the most active product in this series. 
During the “double drugs” SAR studies has it been demonstrated that in spite of some 
derivatives were characterized by excellent plasmepsin inhibition, they showed no 
antimalarial activity. This observation has led us to examine if the plasmepsins were actually 
the target of the “double drugs” synthesized. 
Starting from IM43 (Table 2.2) was undertaken a study that led to the replacement of the 
amino acid statin with leucine, obtaining NV165. Unespectantly, an increase in malaria 
activity has been observed, demonstrating that the “double drugs”  were acting on a different 
target and that statin was not essentianl for the “double drugs” antimalarial activity. 
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Compound R R’ 
D10 
IC50 
(nM) 
W2 
IC50 
(nM)
IM43 
  
230 280 
NV165 
HN
H
N
N
H
NH
O
O
N
O  
36.8 103.9
FG30 
  
345 143 
NV197 
  
357 314 
Table 2.2 
 
The Professor Romeo’s laboratory decided to continue the SAR studies considering NV165 as 
the new lead compound. 
For the SAR studies NV165 has been divided into three parts: the oxybisbenzoic system in 
the center and the two residues R and R' on the sides of the aromatic system. The aromatic 
system derived by 4,4'-oxybisbenzoic acid has not been modified since considered essential 
for the activity59, but have been differentiated in the substituents R and R'. 
It was initially varied the substituent R keeping constant the two amino acids and varying the 
quinoline system in order to verify its activity (FG30).  
The replacement of the quinoline system with an aliphatic diamine resulted in a reduction of 
the antimalarial activity, in particular against D10 strain. Anyway, it has allowed us to 
demonstrate that quinoline is not essential for the parasite growth inhibition. Subsequently the 
number and type of amino acids were varied, in order to obtain molecules with lower 
molecular weight and reduced peptidic character. 
NV197, which was obtained removing two amino acids, one from the substituent R' and one 
from the substituent R, has a molecular weight reduced by one third compared to NV165 
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while maintaining a good antimalarial activity. This compound has been considered for 
further SAR studies of the substituent R'. 
From the subsequent SAR studies (Table 2.3) it was demonstrated that only one amino acid at 
the sides of the oxybisbenzoic system is sufficient to have a good antimalarial activity. In 
particular it has been descovered that leucine methylester group in R' gave the best results 
(AN12). 
 
Compound R 
O
O
O
R R'
 
R’ 
D10 
IC50 
(nM) 
W2 
IC50 
(nM) 
AN12 
 
 
 
12.97 8.46 
AO7 
 
 
 
5.83 2.76 
Table 2.3 
 
AN12 presents a lower molecular weight than NV165 and the antimalarial activity is 
approximately 3 times higher against D10 strains and about 10 times higher agaist W2 strains. 
Considering the AN12 high activity, in subsequent studies the substituent R' was maintained. 
The substituent R was varied, applying the strategy already described. 
The substituent R was divided into two portions: the amino acid and the terminal group that 
were varied alternately. The substitution of leucine with isoleucine residue AO7 has led to an 
increase of antimalarial activity of about 2 times. 
AO7 presents an higher activity than IM43 40 times against D10 strains and 100 times higher 
against W2 strain. 
The SAR studies performed in the Professor Romeo’s laboratory have led to very good 
results, but the molecular target of these compounds is unknown. In order to improve the 
antimalarial activity of this new class of potent compounds it is necessary to know the 
molecular target.  So, chemical proteomics, as previously described, could be a useful tool in 
order to reach this goal. 
Thus the purpose of this first part of my PhD thesis is the identification of the molecular 
target of this new class of potent antimalarial compounds using a chemical proteomics 
approach. 
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In order to reach this goal, first of all different fluorescent lead compound derivatives would 
be synthesized in order to identify the target localization into P. falciparum and thus facilitate 
LC-MS analysis and subsequent database target identification.  
Subsequently a chemical proteomics approach would be performed. There are several 
limitations in chemical proteomics approach that can affect the results. For example, it is 
necessary to use tag compounds that present high activity and affinity for the protein target. 
Moreover considering that LC-MS analysis is a very sensitive methodology that can be used 
for protein target identification, the high background noise caused by non specific protein 
binding could greatly complicate the proteomic analysis. 
Thus in order to overcome these problems we have considered that it is necessary to use a 
chemical proteomics methodology that would allow us to recognize target protein with high 
selectivity. In particular, we have considered that could be useful for us to use a cleavable 
linker between the tag compound and the generally used biotin unit in order to confer high 
selectivity as previously described by Ki Duk Park60. 
In particular we decided to follow the experimental procedure represented in the scheme 
below (Figure 6): 
 
 
Figure 6: Experimental procedure 
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According to this procedure an active alkyne derivate will be incubated into a P. falciparum 
lysate. After that, a suitable cleavable linker will be designed and synthesized in order to fish 
the incubated tag compound with high selectivity using click chemistry. This cleavable linker 
is characterized by a biotin unit, an acylhydrazon cleavable linker and a terminal azide. 
Then the lysate will be purified through an affinity purification column characterized by 
agarose streptavidin beads. 
During the cleavage step, the tag compound will be released with high selectivity thanks to 
the acylhydrazone exchange with acethylhydrazide that belongs only to the incubated 
compound; while the naturally biotinilated proteins, that could be attached to the agarose 
streptavidin beads, will be held into the column. 
Finally LC-MS and databases analysis will be performed in order to identify the protein 
primary sequence or the target protein of this new class of antimalarial compounds. 
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3. Results and Discussion 
3.1 Fluorescent studies: 
The target identification of this new class of potent antimalarial compounds, starts from the 
synthesis of different florescent lead compound derivates in order to identify the target 
localization into P. falciparum and thus facilitate LC-MS and databases analysis.  
The lead compound of this class of antimalarial agents is AN 12, represented below: 
O
H
N
O
O
OH
N
N
H O
O
N
AN 12
IC50 D10= 12.97 nM;
IC50 W2= 8.64 nM  
It is characterized by a high in vitro activity against P. falciparum (IC50 D10= 12.97 nM; IC50 
W2= 8.64 nM). We considered the possibility to introduce three different fluorescent groups 
replacing the N,N-diethylethylendiammine with an ethylendiammine, as spacer, and 
carboxyfluorescein 1, carboxy-coumarine 2 or dansyl 3 as fluorescent tags. 
The antimalarial activity against P. falciparum D10 and W2 strains has been tested in the 
Professor Taramelli’s laboratory. Compound 1 resulted to be inactive, while compounds 2 and 
3 were characterized by antimalarial activity but elicted only in a micromolar range (table 
3.1), not sufficient to perform fluorescent studies. 
 
 
COMPOUND R D10 
IC50(nM) 
W2 
IC50(nM) 
1 
 
Inactive Inactive 
2 
 
1462 1699 
3 
 
4166 4219 
AN 12 
 
12.97 8.64 
Table 3.1 
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Considering the SAR studies of these fluorescent molecules, the high antimalarial activity 
decrease could be caused by the substitution of the basic nitrogen group (tertiary amine), 
presented in the lead compound, with an amidic nitrogen.  
Among the three fluorescent substituents, the carboxy-coumarine derivative 2 resulted the 
most accepted fluorescent group. 
In parallel studies performed in Professor Romeo’s laboratory, enduring the lead compound 
SAR studies, AO 26, a new lead compound, has been identified: 
 
 
 
This compound is characterized by an higher antimalarial activity against D10 and W2 strains 
than  AN 12 as represented in table 3.2 
 
COMPOUND STRUCTURE D10 IC50(nM) 
W2 
IC50(nM) 
AN 12 12.97 8.64 
AO 26 
 
0.49 0.34 
 
Table 3.2 
 
Thus a new fluorescent compound starting from AO 26 has been synthesized. Considering the 
SAR studies of the previous series of fluorescent compounds, we substituted the methyl ester 
group with a carboxy-coumarine linked to a propylendiamine as spacer obtaining compound 
4. 
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In this case we maintained in the same position the basic tertiary amine group bound to 
isoleucine, that from AO 26  SAR studies seems to be the most accepted aminoacid in that 
position. 
Compound 4 obtained was characterized by a good antimalarial activity (D10; W2 IC50= 
13nM) sufficient to perform fluorescent studies in Professor Taramelli’s laboratory. 
These studies are still in progress and would facilitate LC-MS and database analysis. 
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3.2 Chemical proteomics studies: 
Considering that several limitations can affect chemical proteomics, we decided to follow the 
procedure previously described by Ki Duk Park60. In fact it permits us to identify the target 
with high selectivity and sensitivity. 
This procedure consist in five steps:  
1. the incubation of an alkyne modified lead compound into a cellular lysate;  
2. the capture of this tag compound linked to the target protein, using a suitable probe 
characterized by the presence of a cleavable linker, a biotin unit and a terminal azide 
to permit capture with the alkyne modified lead compound using click chemistry; 
3.  purification using affinity chromatography (agarose streptavidin beads);  
4. selective cleavage  
5.  LC-MS analysis in order to identify protein target.  
Thus we focused our attention on the synthesis of a suitable tag compound characterized by 
the presence of a terminal alkyne group. Considering the previous fluorescent SAR studies, it 
was well evident that, starting from AO 26, the substitution of the lead compound basic 
nitrogen group would have led to inactive compounds. Thus we considered the possibility to 
substitute the methylester group on the other side of the molecule with a propargyl amine, 
analogously to the synthesis of compound 4.  
This substitution led to the synthesis of compound 5 which was less active than AO 26 but 
equal to AN 12 (Table 3.3). Considering the high antimalarial activity of compound 5 we 
presume that it would recognize with high affinity the protein target thus limiting aspecific 
protein binding. 
COMPOUND STRUCTURE D10 IC50(nM) 
W2 
IC50(nM) 
AO 26 
 
0.49 0.34 
AN 12  
 
12.97 8.64 
5 8 12 
 
Table 3.3 
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Accordingly to chemical proteomic procedure that we aimed to follow, we have designed and 
synthesized a suitable probe, compound 6, in order to recognize and release the alkyne tag 
compound linked to the protein target with high selectivity. 
 
 
 
The chemical structure of the cleavable linker allow us to recognize the protein target with 
high selectivity and sensitivity, thus limiting the background noise that usually affects the 
chemical proteomics procedures. 
It is characterized by a terminal azide that permits to capture the alkyne modified lead 
compound through click chemistry. We can capture the alkyne tag compound with high 
selectivity because it is the only compound in the whole proteome that can react with 
compound 6.     
The presence of a poliethylenglycol linker increases the water solubility. Moreover 
achylhydrazon cleavable linker provides selectivity during the cleavage step from the resin. 
Considering that in the P. falciparum lysate there could be other proteins naturally biotinilated 
that could be attached to the resin due to the biotin streptavidin recognition, only the tag 
compound is released from the resin, as it is the only compound characterized by the 
cleavable linker. 
Finally the biotin unit links the streptavidin beads during the affinity chromatography 
purification step. 
In order to verify if compounds 5 and 6 could be useful tools for chemical proteomics 
procedure, first of all we focused our attention on click chemistry reactions. 
We performed this reaction with different conditions (Table 3.4): 
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 5/6 ratio Reaction time Conditions 
Yield of 
compound 
7 
1 1/1 24 h 
• CuSO4 
• Na ascorbate 
• H2O/t-BuOH (1:1) 
No 
reaction 
2 1/1 12 h 
• CuSO4 
• Na ascorbate 
• THF/H2O (1:1) 
15% 
3 1/1 1 h  • CuBr • HEPES pH 7.4 30% 
 
Table 3.4 
 
In case 1 we didn’t observe product formation probably because the two reagents haven’t 
been completely dissolved. Thus in case 2 we introduced THF. In this case we obtained 
compound 7 in 15% yield. Better results have been obtained in case 3 using HEPES solution 
(pH 7.4) and CuBr.  
 
 
 
The expected compound has been obtained in 30% yield. Moreover these are also the best 
conditions to perform the click chemistry reaction in a biological media. 
Before starting the chemical proteomics procedure we considered the possibility to verify if 
the acylhydrazon/acyldrazide exchange occurs. Thus we synthesized again compound 7 and 
then we immobilized it on strptavidin agarose beads. After the exchange step and ESI-Ms 
direct infusion analysis we confirmed that compound 8 was formed. 
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At the moment we are waiting for P. falciparum lysate from Professor Taramelli’s laboratory. 
Future studies will be focused on the application of this chemical proteomics techniques in 
order to identified the biological target of this new class of potent antimalarial compounds
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4. Synthesis 
Compounds (1-3) are characterized by a common fragment (ethylendiamine-leucine-
oxibisbenzoic acid-leucinemethylester) linked to three different fluorescent groups using 
ethylendiamine as linker. 
As shown in table 1, compound 1 is characterized by the common fragment linked to 
carboxyfluoresceine; compound 2 by the common fragment linked to carboxy-coumarine and 
compound 3 by the common fragment linked to dansyl. 
 
 
 
COMPOUND 
 
R 
1 
 
2 
 
3 
 
 
Table 1 
 
Compound  4 is characterized by 1-(2-aminoethyl)pyrrolidine-Isoleucine fragment linked to 
one acid group of 4,4’-oxibisbenzoic acid. The other acid portion is substituted by Leucine 
linked to a propilendiamine as spacer and corboxycoumarin group as shown in the figure 
below.  
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Compound 5 is characterized by 1-(2-aminoethyl)pyrrolidine-Isoleucine fragment linked to 
one acid group of 4,4’oxibisbenzoic acid. The other acid portion is substituted by Leucine 
linked to propargylamine as shown in the figure below. 
 
 
 
Compound 6 is characterized by the biotin unit, acylhydrazon cleavable linker, 
polietylenglycole linker and terminal azide as shown in the figure below. 
 
 
 
Compound 7 is characterized by the 4,4’-oxybisbenzoic acid substituted at one side by a 1-(2-
aminoethyl)pyrrolidine-Isoleucine fragment and on the other side by leucine linked to the 
triazole ring, linked to a polietylenglycole linker-acylhydrazon cleavable linker-biotin unit 
fragment as shown in the figure below. 
 
Compound 8 is characterized by 4,4’-oxybisbenzoic acid substituted on one side by 1-(2-
aminoethyl)pyrrolidine-Isoleucine fragment and on the other side by leucine linked to triazole 
ring, linked to a polietylenglycole and acetydrazide 
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4.1 Reactions and mechanisms 
 
Coupling reaction: 
 
This reaction is a key step in the process of production of peptides, and requires activation of 
the carboxylic acid by means of coupling reagents. 
The "peptide coupling reagents" have evolved significantly over the last 10 years: from 
carbodimmidi salts onium (phosphonium and uronium). The "coupling reagents" (Figure 7) 
can be classified as: 
• Carbodiimmide coupling reagent. 
• Benzotriazoles. 
 
 
Figure 7 
The use of coupling reagents of industrial began in 1955 with the introduction of 
dicloesilcarbodiimmide (DCC). Unfortunately, the carbodiimmide due to the high reactivity 
may cause racemization and secondary coupling reactions (Figure 8). 
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Figure 8 
 
The mechanism of activation of carbodimmide (complex mechanism and solvent dependent) 
begins by the transfer of a proton carbodimmide, followed by the addition of the carboxylate 
to form the O-acilisourea (a) (Figure 8). This is the most reactive species that can attack the 
amine to give the corresponding amide. The O-acilisoura (a) may rearrange to give the N-acyl 
urea (b), which is not reactive or it may undergo an intramolecular cyclization to give 5 (4H)-
ossazolone (c), which is less reactive (as ) and can tautomerize with the corresponding loss of 
chirality (c '). If the activation is conveyed in a solvent with low dielectric constant such as 
CHCl3 or CH2Cl2, the formation of (a) occurs instantaneously and is absent if a nucleophile or 
a base, can remain stable for several hours. If the activation is carried out in the presence of a 
more polar solvent such as DMF, no immediate reactions are found, indeed, can form a 
complex mixture of amino acids initiates as symmetrical anhydrides (d). 
The 1-hydroxybenzotriazole (HOBt) (f) (Figure 7) is used as additive to reduce the DCC for 
racemization, and has recently developed new derivatives benzotriazoles as 1-hydroxy-5-
chlorobenzotriazole (Cl-HOBt) (g) or 1 -hydroxy-7-azabenzotriazolo (HOAT) (s). 
The HOBt active esters (s) (Figure 8) are less reactive intermediate (a), but more stable and 
less ready to racemize.  
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The addition of benzotriazoles [HOBt (f) and Cl-HOBt (g)] (Figure 7) to the carbodimmide 
coupling reagent leads to the formation of the active ester of benzotriazole, which is less 
reactive O-acilisourea (a) (Figure 8), reducing the racemization of the protected amino acids 
and avoiding the formation of other less reactive derivatives. The Cl-HOBt (g) functions as 
the HOBt (f) (Figure 7), although it is much more acid (pKa: 3.35 for Cl-HOBt and 4.60 for 
HOBt), is a better leaving group and the active esters are more reactive than HOBt esters. 
The Cl-HOBt is used as additive along with the HBTU (m) (Figure 8) to suppress 
racemization during the realization of coupling.  
The pyridine derivatives of HOBt (HOAT) are not suitable for industrial use, because the 
presence of nitrogen in the aromatic ring makes the structure unstable. 
In the last decade the salts (phosphonium and uronium) of hydroxybenzotriazole derivatives 
were introduced in the market (HBTU, TBTU, HATU). The species that reacts with the salt is 
the carboxylate (Figure 9) and therefore it is essential the presence of a minimum amount of 
base for acid deprotonation. The intermediate species of acyloxy-phosphonium salts, which 
have not been isolated, they react immediately with the benzotriazolic derivative to give (e) 
(Figure 8), which reacts with the component Ilino ammonium to give the corresponding 
amide. 
 
 
Figure 9 
 
The use of more reactive salt HATU (q) (Figure 7) presents the disadvantage of the high 
price. HCTU (o)\TCTU (p) (Figure 7) are a good alternative to HBTU (m)\TBTU (n) (Figure 
7), because the presence of Cl-HOBt makes these reagents more reactive. 
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Click chemistry reaction: 
 
"Click Chemistry" is a term that was introduced by K. B. Sharpless in 2001 to describe 
reactions that are high yielding, wide in scope, create only byproducts that can be removed 
without chromatography, are stereospecific, simple to perform, and can be conducted in easily 
removable or benign solvents. This concept was developed in parallel with the interest within 
the pharmaceutical, materials, and other industries in capabilities for generating large libraries 
of compounds for screening in discovery research. Several types of reaction have been 
identified that fulfill these criteria, thermodynamically-favored reactions that lead specifically 
to one product, such as nucleophilic ring opening reactions of epoxides and aziridines, non-
aldol type carbonyl reactions, such as formation of hydrazones and heterocycles, additions to 
carbon-carbon multiple bonds, such oxidative formation of epoxides and Michael Additions, 
and cycloaddition reactions. 
As one of the best click reactions to date, the copper-catalyzed azide-alkyne cycloaddition 
features an enormous rate acceleration of 107 to 108 compared to the uncatalyzed 1,3-dipolar 
cycloaddition. It succeeds over a broad temperature range, is insensitive to aqueous conditions 
and a pH range over 4 to 12, and tolerates a broad range of functional groups. Pure products 
can be isolated by simple filtration or extraction without the need for chromatography or 
recrystallization. 
 
 
 
The active Cu(I) catalyst can be generated from Cu(I) salts or Cu(II) salts using sodium 
ascorbate as the reducing agent. Addition of a slight excess of sodium ascorbate prevents the 
formation of oxidative homocoupling products. Disproportionation of a Cu(II) salt in presence 
of a Cu wire can also be used to form active Cu(I). 
DFT calculations have shown that coordination of Cu(I) to the alkyne is slightly endothermic 
in MeCN, but exothermic in water, which is in agreement with an observed rate acceleration 
in water. However, coordination of Cu to the acetylene does not accelerate a 1,3-dipolar 
cycloaddition. Such a process has been calculated to be even less favorable than the 
uncatalyzed 1,3-dipolar cycloaddition. Instead, a copper acetylide forms, after which the azide 
  Synthesis 
      47 
 
displaces another ligand and binds to the copper. Then, an unusual six-membered copper(III) 
metallacycle is formed. The barrier for this process has been calculated to be considerably 
lower than the one for the uncatalyzed reaction. The calculated rate at room temperature is  
1s-1, which is quite reasonable. Ring contraction to a triazolyl-copper derivative is followed 
by protonolysis that delivers the triazole product and closes the catalytic cycle (Figure 10). 
 
 
Figure 10: Catalytic cycle 
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4.2 Schemes of synthesis 
 
Compounds 1-3 synthesis: 
The synthesis of compounds 1-3 started from the synthesis of a common fragment,  
intermediate 12: 
 
Intermediate 12 has been synthesized using a coupling reaction between intermediate 9 and 
intermediate 11 deprotected from the Boc group using HCl 4N in dioxane. Intermediate 9 has 
been obtained from the coupling reaction between Leucine-methylester and 4,4’-
oxibisbenzoic acid. Intermediate 11 has been synthesized by coupling Boc-leucine with 
intermediate 10 obtained from the reaction between etylendiamine and benzylchloroformate.  
Then intermediate 12 has been deprotected using catalytic hydrogenation obtaining common 
fragment A: 
 
 
  Synthesis 
      49 
 
Fragment A was coupled with carboxy-fluoresceine obtaining compound 1; with carboxy-
coumarine obtaining compound 2 and with dansyl obtaining compound 3  
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Compound 4 synthesis: 
Compound 4 has been synthesized coupling carboxy-coumarine and intermediate 17 
previously deprotected using catalytic hydrogenation. Intermediate 17 has been synthesized 
coupling deprotected intermediate 14 and intermediate 16. 
Intermediate 14 has been synthesized with coupling reaction between Boc-leucine and 
intermediate 13 obtained thanks to coupling reaction between propilendiamine and 
benzylchlorophormiate.  
Intermediate 16 has been synthesized coupling 4,4’-oxybisbenzoic acid and previously 
deprotected intermediate 13 obtained thanks to coupling reaction between 1-(2-
aminoethyl)pyrrolidine and Boc-isoleucine. 
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Compound 5 synthesis: 
Compound 5 has been synthesized coupling Boc-deprotected intermediate 18, obtained by 
coupling reaction between propargilamine and Boc-leucine, with intermediate 20 deprotected 
using catalytic hydrogenation.  
Intermediate 20 has been synthesized coupling Boc-deprotected intermediate 15, obtained by 
coupling reaction between 1-(2-aminoethyl)pyrrolidine and Boc-isoleucine, with intermediate 
19 obtained by the reaction between 4,4’oxibisbenzoic acid and benzyl bromide. 
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Synthesis of compound 6: 
Compound 6 has been synthesized stirring overnight a solution of intermediate 23 in CH2Cl2  
and a solution of intermediate 25 in THF/H2O (1:1). 
The synthesis of intermediate 23 started from the reaction between tetraethylene glycol and p-
toluenesulfonyl chloride at 0°C obtaining intermediate 21. This intermediate has been treated 
with NaN3 at 70°C obtaining intermediate 22 that has been oxidized, trough Swern oxidation 
reaction, obtaining intermediate 23. 
Intermediate 25 has been synthesized treating intermediate 24, obtained from biotin 
esterification reaction, with NH2NH2 in MeOH. 
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Synthesis of compound 7: 
Compound 7 has been synthesized with click chemistry reaction between compound 6 and 
compound 5. The synthesis of these compounds has been described above. 
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4.3 Proteomic reactions: method 
A typical chemical proteomics experiment starts immobilizing a bioactive compound on a 
matrix, such as sepharose or agarose.  
There are various commercially available activated resins that allow the attachment of 
specific chemical groups (for example, sulfhydryl, amino, hydroxyl or carboxyl groups). 
When a compound needs to be modified for immobilization, it is important to follow up this 
modification chemistry with an appropriate biochemical or cell-based assay to ensure that 
activity is retained.  
In parallel, a cell extract is prepared either from cells or tissue. Subsequently, this lysate is 
incubated with the affinity matrix and washed extensively before elution. Depending on the 
experimental strategy, washes of different stringencies are used. Detergents, salts or 
denaturing agents can be used for nonspecific elution. More specific elution can be achieved 
by competition with an excess of soluble compound or via specific cleavage of an engineered 
linker. 
Processing by SDS-PAGE (one- or two-dimensional) or a gel-free method (‘shotgun 
proteomics’) and subsequent digest of the proteins with a protease, typically trypsin, generates 
a complex peptide mixture that is then analyzed by nano-HPLC coupled to nano-ESI-
MS/(MS). The results are searched against an appropriate protein database (for example, 
SwissProt or the US National Center for Biotechnology Information) with a search engine 
(for example, Mascot or Sequest) before being submitted to a more in-depth bioinformatic 
analysis. 
 
4.4 Proteomic reactions: scheme of synthesis 
Synthesis of compound 8: 
Compound 8 has been synthesized starting from the click chemistry reaction between 
compound 5 and compound 6 obtaining compound 7. This compound has been immobilized 
on agarose strptavidine beads due to selective recognition between compound 7 biotin portion 
and streptavidin. The final compound has been obtained through the selective cleavage due to 
acylhydrazone exchange with acetyldrazide and subsequent reduction with NaCNBH3. 
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5. Conclusions 
 
In this first part of my PhD thesis I have set up a chemical proteomics methodology in order 
to identify the biological target of potent antimalarial compounds that were synthesized in 
Professor Romeo’s laboratory.  
The identification of the biological target is the first step necessary to start rational SAR 
studies. Furthermore, this might lead to the identification of a new target for the development 
of different therapeutics. 
In the last decade different approaches have been attempted in order to identify the target of 
various antimalarial drugs, but has not been obtained any result yet. 
As an example, O’Neal et al 61 focused their attention on the identification of the target of the 
antimalarial artemisinin. In particular, within their research, they have focused on the 
preparation of activity based probes of artemisinin and trioxolane incorporating a biotin 
moiety for streptavidin affinity “pull down” of covalently tagged target proteins. They have 
also developed methodology for the integration of a cleavable linker between the biotin tag 
and the site of attachment to the target protein to permit mild elution of probe labeled proteins 
and direct identification by HPLC-MS/MS. At the moment it is not yet published any results. 
The majority of failures in applying chemical proteomics approaches to malaria can be caused 
by several factors. 
First, the system Plasmodium-host red blood cell is a complex biological system characterized 
by heterogeneous proteins. In addition the parasite is characterized by a complex growth 
mechanism that develops in several stages and each stage is characterized by different 
proteins that may or not be expressed.  Moreover in the cell lysate there is often the hemozoin, 
characterized by a core of iron that can cause interference especially when using a proteomic 
approach characterized by magnetic separations. 
In addition proteomic searches using affinity-based chromatography have been severely 
hampered by low protein recovery yields, protein destruction and denaturation, and the 
release of background proteins from the support that confound protein identification. 
Thus, to identify a protein target in a biologically complex system like Plasmodium 
falciparum could be useful to follow a chemical proteomics approach which is characterized 
by high selectivity and sensitivity. 
The methodology set up during my PhD thesis is characterized by high selectivity and 
sensitivity as demonstrated by preliminary tests. 
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In details, the selectivity is due to the presence of an azido cleavable linker, that can recognize 
with high selectivity the alkyne modified lead compound using click chemistry. Moreover, 
during the cleavage step, it can release from the streptavidine beads only the proteins that 
effectively reacted with the modified lead compound. 
In addition, the alkyne modified lead compound would recognize with high selectivity the 
protein targets, thanks to its high activity, limiting aspecific protein binding and thus the 
presence of background proteins that would greatly complicate the protein identification. 
The sensitivity of this method is due to the HPLC-MS/MS analysis that will be performed 
using an high resolution, high sensitivity mass spectrometer, the LTQ-Orbitrap, able to 
analyze till 5-10 pM concentrations. 
So, future studies will apply this chemical proteomic approach on a P. falciparum lysate, 
prepared by Professor Taramelli’s laboratory, in order to identify the protein target or at least 
its primary sequence, using SDS-PAGE and HPLC-MS/MS analysis. 
Experimental section 
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6. Experimental section 
 
6.1. Abbreviations, materials and methods 
Bd: doublet broadened s: singlet, t: triplet, bs: broadened singlet, d: doublet, dd: double 
doublet, m: multiplet, bm: multiplet expanded, ppm: parts per million; Boc: tert-
butoxycarbonyl, Cbz: benzyloxycarbonyl ; Rf: retention factor; AcOEt: ethyl acetate; DMF: 
dimethylformamide; DMSO: dimethylsulfoxide TEA: triethylamine; HBTU: 2 - (1H-
benzotriazol-1-yl) -1,1,3,3-tetramethyluronium hexafluorophosphate; Et2O: diethyl ether; 
HOBt: 1-hydroxybenzotriazole; NMM: N-methylmorpholine; TLC: thin layer 
Chromatography; TBTU: O-(Benzotriazole-1-yl)-N, N, N ', N'-tetramethyluronium 
tetrafluoroborate; MeOH: methanol; Pd / C: palladium on carbon. 
 
For TLC was used silica gel 60 F254 supported on aluminum sheets (Merck). 
The flash chromatographic columns were carried out using gel silice60 (0040-0063 mm, 
Merck). 
The reagents were purchased from: Sigma Aldrich, Acros, Fluka and Iris Biotech. 
 
The NMR spectra were recorded at 300 MHz NMR Varian Mercury 300 instrument using VX 
using as solvent DMSO-d6 or CDCl3. The peaks were assigned by NMR spectroscopy-
dimensional (COSY), which is compatible with the structure under examination. 
The display of TLC was carried out using a UV ray lamp and Camag immersion in 2% 
phosphomolybdic acid in ethanol. 
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6.2. General procedures for synthesis 
 
A: Amide bound formation: 
 
 
 
The carboxylic acid (1.1 eq) and the amine (1.0 eq) are dissolved under nitrogen in an appropriate 
solvent (DMF or dichloromethane) (5mL/mmol), N-methylmorpholine was then added followed by 
hydroxybenzotriazole solution (HOBt) (1.5 eq). The resulting solution was cooled at 0 °C and O-
(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HBTU) was added (1.1 eq). 
The mixture was then stirred at room temperature overnight. Dichloromethane was then added and the 
organic phase washed with HCl 1N, saturated NaHCO3, water, brine, dried, filtered and concentrated. 
 
B: Removal of the Cbz group by catalytic hydrogenation 
 
R NH2R N
H
O
O
H2, Pd/C 10%
CH3OH
 
 
The Cbz protected compound was dissolved in methanol (10 mL/mmol) and then Pd/C (10%) 
(80 mg/mmol) was added. When the reaction was completed (30-40 min) the mixture was 
filtrated, washed with methanol and the residue concentrated and used in the next step without 
any further purification or characterization. 
 
C: Removal of the Boc group 
 
 
 
After cooling the Boc protected compound at 0 °C, HCl 4N in dioxane was added (10 mL/g of 
compound). The mixture was stirred at room temperature for 30 minutes, after this time the 
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mixture was concentrated and the resi*due washed 3 times with ethyl ether and used in the 
next step without any further purification or characterization. 
 
D: 4,4’oxybisbenzoic acid monosostitution 
 
  
 
4,4 'oxybisbenzoic acid (1 eq.) and the amino acid (1 eq.) are placed in a flask equipped with 
a CaCl2 valve. Subsequently they are solubilized in DMF (5 ml for each mmole). The flask is 
placed in an ice bath to cool the reaction environment before any further additions. TBTU (0.8 
eq.) and NMM (3 eq.) are added  to pH ≥ 7. The reaction mixture is stirred at room 
temperature for 1:40 h. The organic phase was then dried and dissolved in CH2Cl2. 
Subsequently the solution was washed with HCl 1N (3 washes) and a saturated solution of 
NaCl. The organic phase was then dried over Na2SO4, filtered and dried under vacuum. 
 
E: Monoamine acylation 
 
 
 
The diamine (1 eq) is dissolved in DCM (8.8 ml/g) and the solution is cooled in a ice bath. A 
solution of benzilchlorophormiate (3 eq) in DCM is added dropwise over 20 min. The ice bath 
is removed. The reaction mixture is stirred overnight and extracted with H2O. The crude 
product is purified by silica gel flash chromatography. 
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6.3 General procedures for target identification 
F: Click chemistry reaction 
 
 
 
A 5 mM solution (5% CH3CN/HEPES pH 7.4) of azido-compound is added to a 25 μM 
solution (HEPES 50 mM ph 7.4) of alkyne compound. Then CuBr is added and the reaction 
mixture is vigorously stirred at room temperature for 1h. At the end of the reaction the 
solution appears blu. 
 
G: Immobilization on agarose streptavidin beads 
Agarose streptavidin beads is packed into a Pierce Centrifuge column and the column is then 
placed into a collection tube. The system is centrifuged at 500 rpm for 1 min to remove the 
storage solution. One column volume (1 ml) of binding buffer (Phosphate-buffer saline) is 
added on the top of the resin bed. The suspension is centrifuged at 500 rpm for 1 min to 
remove the buffer. This step is repeated two times discarding buffer from collection tube. 
The column is placed in a new collection tube and the sample is added and incubated at room 
temperature for 10 min. The column is washed with one column volume of binding buffer and 
centrifuged at 500 rpm for 1 min. This step is repeated four times discarding buffer from the 
collection tube.  
 
H: Acylhydrazon cleavage 
The agarose streptavidin beads are washed with HEPES 15 mM pH 7.4 (10 times, 0.8 ml) 
centrifuging 1 min at 1000 rpm. HEPES 50 mM is added and the resin is incubated 4h at 37°C 
with acetyldrazine and p-anisidine gently shaken. 
The supernatant (50 ml) was treated with a 10 mM solution of NaCNBH3 (50 ml) in 50 mM 
NaOAc buffer (pH 3.8) and shacked at room temperature (2 h).  
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Intermediate 9 
(S)-4-(4-(1-methoxy-4-methyl-1-oxopentan-2-ylcarbamoyl)phenoxy)benzoic 
acid 
 
 
 
The intermediate 9 has been obtained following general procedure D and using the subsequent 
reagents: 
 
• 1.40 g Leucine methylester HCl, 7.74 mmol (1eq) 
• 2,00 g Oxybisbenzoic acid, 7.74 mmol (1eq) 
• 11 ml DMF 
• 1.98 g TBTU, 6.19 mmol (0.8 eq) 
• 3.41 ml NMM, 30.96 mmol (4 eq) 
 
The reaction have been controlled using TLC, CH2Cl2/CH3OH (90:10) and extracted with 
CH2Cl2. The crude product was purified by silica gel flash chromatography 
(CH2Cl2/MeOH+10%NH3, from 99:1 to 95:5). The intermediate was a yellow oil. The 
reaction yield was 28.2% 
 
1H NMR (300 MHz, DMSO) δ 8.73 (d, J = 7.4 Hz, 1H), 7.97 (d, J = 8.3 Hz, 4H), 7.15 (dd, J = 22.2, 8.5 Hz, 
4H), 4.60 – 4.41 (m, 1H), 3.64 (s, 3H), 1.86 – 1.50 (m, 3H), 0.90 (dd, J = 13.5, 6.2 Hz, 6H). 
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Intermediate 10 
benzyl 2-aminoethylcarbamate 
O N
H
NH2
O
 
 
The intermediate 10 has been obtained following general procedure E and using the 
subsequent reagents: 
 
• 2 g Ethylendiammine, 33.27 mmol 1 (eq) 
• 2.45 g Benzychlorophormiate, 14.41 mmol (3eq) 
• 19.74 ml DCM 
 
The reaction have been controlled using TLC, CH2Cl2/CH3OH (90:10) and extracted with 
H2O. The crude product was purified by silica gel flash chromatography 
(CH2Cl2/MeOH+10%NH3, from 99:1 to 85:15). The intermediate was a white solid. The 
reaction yield was 22% 
 
1H NMR (300 MHz, CDCl3) δ 7.46 – 7.28 (m, 5H), 5.10 (s, 4H), 3.26 (dd, J = 11.5, 5.7 Hz, 2H), 2.83 (t, J = 5.9 
Hz, 2H). 
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Intermediate 11 
(S)- ter-butyl N-(1-(2-((benzyloxy)carbonil)amino)ethyl)carbamoyl)-3-
methylbutyl)carbamate 
 
O N
H
H
N
O
N
H
O
O
O
 
 
The intermediate 11 has been obtained coupling intermediate 10 and BocLeuOH following 
general procedure A and using the subsequent reagents: 
 
• 0.852 g BocLeuOH, 3.41 mmol (1.1 eq) 
• 0.640 g intermediate 10; 3.109 mmol (1 eq) 
• 0.713 g HOBT, 4.663 mmol (1.5 eq) 
• 1.415 g HBTU, 3.730 mmol (1.2 eq) 
• 7 ml DMF 
• 1.36 ml NMM, 12.43 mmol (4 eq) 
 
The reaction have been controlled using TLC, CH2Cl2/CH3OH (90:10) and extracted with 
CH2Cl2. The crude product was purified by silica gel flash chromatography 
(CH2Cl2/MeOH+10%NH3, from 99:1 to 85:15). The intermediate was a yellow oil. The 
reaction yield was 58.% 
 
1H NMR (300 MHz, CDCl3) δ 7.40 – 7.28 (m, 5H), 6.64 (s, 1H), 5.32 (d, J = 26.5 Hz, 1H), 5.09 (s, 2H), 4.89 (s, 
1H), 4.03 (d, J = 4.2 Hz, 1H), 3.52 – 3.21 (m, 4H), 1.65 (dd, J = 12.0, 6.5 Hz, 2H), 1.51 – 1.34 (m, 10H), 0.99 – 
0.82 (m, 6H). 
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Intermediate 12 
(S)-methyl 2-(4-(4-((S)-1-(2-(benzyloxycarbonylamino)ethylamino)-4-
methyl-1-oxopentan-2-ylcarbamoyl)phenoxy)benzamido)-4-
methylpentanoate 
 
 
 
The intermediate 12 has been obtained coupling (general procedure A) intermediate 9 and 
intermediate 11, previously deprotected using procedure C. 
 
For the deprotection reaction have been used the following reagents: 
• 8.07 ml HCl in dioxane anidre 
• 0.807 g intermediate 11, 1.98 mmol (1 eq)  
For the coupling reaction have been used the following reagents: 
• 0.843 g intermediate 9, 2.18 mmol (1.1 eq) 
• 0.901 g HBTU,  2.376 mmol (1.2 eq) 
• 5 ml DMF 
• 0.654 ml NMM, 5.94 mmol (3 eq) 
 
The reaction have been controlled using TLC, CH2Cl2/CH3OH (90:10) and extracted with 
CH2Cl2. The crude product was purified by silica gel flash chromatography 
(CH2Cl2/MeOH+10%NH3, from 99:1 to 95:5). The intermediate was a white solid. The 
reaction yield was 43.7.% 
 
1H NMR (300 MHz, CDCl3) δ 7.85 – 7.70 (m, 4H), 7.37 – 7.27 (m, 4H), 7.08 (s, 1H), 6.91 (d, J = 8.6 Hz, 5H), 
5.40 (s, 1H), 5.30 (s, 1H), 5.12 – 4.99 (m, 2H), 4.83 (dd, J = 14.8, 7.0 Hz, 1H), 4.66 (d, J = 5.7 Hz, 1H), 3.77 (s, 
3H), 3.32 (s, 4H), 1.88 – 1.58 (m, 6H), 0.98 (dd, J = 12.3, 4.9 Hz, 12H). 
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Compound 1 
(S)-methyl 2-(4-(4-((S)-1-(2-(3,6-dihydroxy-3'-oxo-3'H,10H-
spiro[anthracene-9,1'-isobenzofuran]-4'-ylcarboxamido)ethylamino)-4-
methyl-1-oxopentan-2-ylcarbamoyl)phenoxy)benzamido)-4-
methylpentanoate 
 
 
 
Compound 1 has been obtained coupling (general procedure A) carboxy-fluoresceine and 
intermediate 12, previously deprotected using procedure B. 
 
For the deprotection reaction have been used the following reagents: 
• 2.41 ml MeOH  
• 0.019 g Pd/C 
• 0.162 g intermediate 12, 0.241 mmol (1.1 eq) 
For the coupling reaction have been used the following reagents: 
• 0.100 g carboxy-fluoresceine, 0.265 mmol (1 eq) 
• 0.110 g HATU, 0.289 mmol (1.2 eq) 
• 1 ml DMF 
• 96.5 ml NMM, 1.205 mmol (5 eq) 
 
The reaction have been controlled using TLC, CH2Cl2/CH3OH (90:10) and digested with 
CH2Cl2. The product have been than crystallized from CH2Cl2. No further purifications have 
been done. 
 
1H NMR (300 MHz, DMSO) δ 10.16 (s, 2H), 8.88 – 8.56 (m, 1H), 8.56 – 8.30 (m, 1H), 7.95 (d, J = 6.7 Hz, 
4H), 7.69 – 7.28 (m, 1H), 7.19 – 6.99 (m, 4H), 6.66 (dd, J = 39.7, 23.2 Hz, 4H), 5.76 (s, 2H), 4.49 (s, 2H), 3.64 
(s, 4H), 3.33 (s, 9H), 1.90 – 1.41 (m, 6H), 1.18 – 0.66 (m, 12H). 
Experimental section 
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Compound 2 
(S)-methyl 2-(4-(4-((S)-1-(2-(7-(diethylamino)-2-oxo-2H-chromene-3-
carboxamido)ethylamino)-4-methyl-1-oxopentan-2-
ylcarbamoyl)phenoxy)benzamido)-4-methylpentanoate 
 
 
 
Compound 2 has been obtained coupling (general procedure A) carboxy-coumarine and 
intermediate 12, previously deprotected using procedure B. 
 
For the deprotection reaction have been used the following reagents: 
• 2.0 ml MeOH  
• 0.016 g Pd/C 
• 0.116 g intermediate 12, 0.173 mmol (1 eq) 
For the coupling reaction have been used the following reagents: 
• 0.050g carboxy-coumarine, 0.191 mmol (1.1 eq) 
• 0.079 g HATU, 0.208 mmol (1.2 eq) 
• 0.8 ml DMF 
• 0.076 ml NMM, 0.692 mmol (4 eq) 
 
The reaction have been controlled using TLC, CH2Cl2/CH3OH (90:10) and extracted with 
CH2Cl2. The crude product was purified by silica gel flash chromatography (CH2Cl2/MeOH, 
from 100 to 97:3). The intermediate was a yellow solid. The reaction yield was 56.6.% 
 
1H NMR (300 MHz, CDCl3) δ 9.04 (d, J = 5.6 Hz, 1H), 8.57 (s, 1H), 7.82 (dd, J = 11.2, 8.7 Hz, 4H), 7.41 (d, J 
= 8.9 Hz, 1H), 7.01 (d, J = 7.2 Hz, 4H), 6.80 (d, J = 8.1 Hz, 1H), 6.69 (d, J = 8.9 Hz, 1H), 6.61 – 6.47 (m, 1H), 
4.90 – 4.80 (m, 1H), 4.77 – 4.64 (m, 1H), 3.77 (s, 3H), 3.67 – 3.36 (m, 8H), 1.91 – 1.60 (m, 6H), 1.29 – 1.17 (m, 
6H), 1.03 – 0.90 (m, 12H). 
Experimental section 
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Compound 3 
(S)-methyl 2-(4-(4-((S)-1-(2-(5-(dimethylamino)naphthalene-1-
sulfonamido)ethylamino)-4-methyl-1-oxopentan-2-
ylcarbamoyl)phenoxy)benzamido)-4-methylpentanoate 
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Compound 3 has been obtained coupling (general procedure A) dansyl and intermediate 12, 
previously deprotected using procedure B. 
 
For the deprotection reaction have been used the following reagents: 
• 5.0 ml MeOH  
• 0.040 g Pd/C 
• 0.192 g intermediate 12, 0.285 mmol (1 eq) 
For the coupling reaction have been used the following reagents: 
• 0.100 g dansyl, 0.370 mmol (1.3 eq) 
• 10 ml DCM 
• 0.06 ml NMM, 0.57 mmol (2 eq) 
 
The reaction have been controlled using TLC, CH2Cl2/CH3OH (90:10). The crude product 
was purified by silica gel flash chromatography (CH2Cl2/MeOH, from 100 to 97:3). The 
intermediate was a yellow solid. The reaction yield was 58.5% 
 
1H NMR (300 MHz, CDCl3) δ 8.58 (s, 2H), 8.43 – 8.29 (m, 1H), 8.18 (d, J = 7.1 Hz, 1H), 7.92 – 7.71 (m, 5H), 
7.61 – 7.43 (m, 2H), 7.20 (s, 1H), 7.08 – 6.78 (m, 5H), 6.13 (s, 1H), 4.84 (d, J = 11.0 Hz, 1H), 4.57 (d, J = 6.7 
Hz, 1H), 3.78 (s, 3H), 3.31 (dd, J = 24.9, 16.5 Hz, 2H), 3.23 – 2.99 (m, 2H), 2.98 – 2.80 (m, 6H), 1.75 (dd, J = 
22.9, 18.2 Hz, 6H), 0.95 (dd, J = 15.3, 3.6 Hz, 12H). 
Experimental section 
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Intermediate 13 
benzyl 3-aminopropylcarbamate 
 
 
 
The intermediate 13 has been obtained following general procedure E and using the 
subsequent reagents: 
 
• 3.0 g diaminopropane, 36,00 mmol (3 eq) 
• 2.21 g benzylchlorophormiate, 12,00 (1 eq) 
• 26.6 ml DCM 
 
The reaction have been controlled using TLC, CH2Cl2/CH3OH (90:10) and extracted with 
H2O. No further purifications have been done. The reaction yield was 78.5% . 
 
1H NMR (300 MHz, CDCl3) δ 7.34 (s, 5H), 5.13 (d, J = 22.9 Hz, 4H), 3.35 – 3.15 (m, 2H), 2.79 (dd, J = 12.8, 
6.4 Hz, 2H), 1.73 – 1.58 (m, 2H). 
Experimental section 
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Intermediate 14 
(S)-ter-butyl N-(1-(3-((benzyloxy)carbonil)amino)propyl)carbamoyl)-3-
methylbutyl)carbamate 
 
 
The intermediate 14 has been obtained coupling intermediate 13 and Boc-Leucine following 
general procedure A and using the subsequent reagents: 
 
• 0.466 g intermediate 13, 2.240 mmol (1 eq) 
• 0.569 g BocLeuOH, 2.462 mmol (1.1 eq) 
• 1.024 g HBTU, 2.69 mmol (1.2 eq) 
• 0.466 g HOBT, 3.40 mmol (1.5 eq) 
• 10 ml DCM 
• 0.490 ml NMM, 4.480 mmol (4 eq) 
 
The reaction have been controlled using TLC, CH2Cl2/CH3OH (90:10) and extracted with 
CH2Cl2. The crude product have been digested with Et2O. No further purification have been 
done. The reaction yield was 90.0%. 
 
1H NMR (300 MHz, CDCl3) δ 7.38 – 7.28 (m, 5H), 5.09 (s, 2H), 4.04 (s, 1H), 3.38 – 3.13 (m, 4H), 1.65 (dd, J = 
14.3, 8.3 Hz, 4H), 1.45 (d, J = 14.3 Hz, 10H), 0.93 (d, J = 3.9 Hz, 6H). 
Experimental section 
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Intermediate 15 
tert-butyl (2S,3R)-3-methyl-1-oxo-1-(2-(pyrrolidin-1-yl)ethylamino)pentan-
2-ylcarbamate 
 
 
 
The intermediate 15 has been obtained coupling 1-(2-aminoethyl)pyrrolidine and Boc-
Isoleucine following general procedure A and using the subsequent reagents: 
 
• 3.00 g BocIleOH, 12.97 mmol (1.1 eq) 
• 2.69 g 1-(2-aminoethyl)pyrrolidine, 23.58 mmol (2 eq) 
• 2.38 g HOBT, 17.68 mmol (1.5 eq) 
• 4.54 g TBTU, 14.14 mmol (1.2 eq) 
• 10 ml DCM 
• 3 ml NMM, 27.11 mmol (2.5eq) 
 
The reaction have been controlled using TLC, CH2Cl2/CH3OH (90:10) and extracted with 
CH2Cl2. The crude product have been digested with Et2O/AcOEt. No further purification have 
been done. The reaction yield was 79.0% 
 
1H NMR (300 MHz, CDCl3) δ 6.48 (s, 2H), 4.02 – 3.83 (m, 1H), 3.45 – 3.28 (m, 2H), 2.70 – 2.44 (m, 6H), 1.78 
(s, 5H), 1.46 (d, J = 20.4 Hz, 11H), 0.90 (t, J = 7.0 Hz, 6H). 
Experimental section 
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Intermediate 16 
4-(4-((2S,3R)-3-methyl-1-oxo-1-(2-(pyrrolidin-1-yl)ethylamino)pentan-2-
ylcarbamoyl)phenoxy)benzoic acid 
 
 
Intermediate 16 has been obtained coupling (general procedure D) 4,4’-oxybisbenzoic acid 
and intermediate 15, previously deprotected using procedure C. 
 
For the deprotection reaction have been used the following reagents: 
• 10 ml HCl in dioxane anidre 
• 1.016 g intermediate 15, 3.10 mmol (1 eq) 
For the coupling reaction have been used the following reagents: 
• 0.800 g 4,4’oxybisbenzoic acid, 3.10 mmol (1 eq) 
• 1.175 g HBTU, 3.10 mmol (1 eq) 
• 7 ml DMF 
• 2 ml NMM, 18.6 mmol (6 eq) 
 
The reaction have been controlled using TLC, CH2Cl2/CH3OH (90:10). The crude product 
was purified by silica gel flash chromatography (CH2Cl2/MeOH, from 99:1 to 97:3). The 
intermediate was a white solid. The reaction yield was 59%. 
 
1H NMR (300 MHz, CDCl3)  δ 7.85 – 7.70 (m, 4H), 7.37 – 7.27 (m, 4H) δ 6.48 (s, 2H), 4.02 – 3.83 (m, 1H), 
3.45 – 3.28 (m, 2H), 2.70 – 2.44 (m, 6H), 1.78 (s, 5H), 1.46 (m, 2H), 0.90 (t, J = 7.0 Hz, 6H). 
Experimental section 
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Intermediate 17 
benzyl 3-((S)-4-methyl-2-(4-(4-((2S,3R)-3-methyl-1-oxo-1-(2-(pyrrolidin-1-
yl)ethylamino)pentan-2-
ylcarbamoyl)phenoxy)benzamido)pentanamido)propylcarbamate 
 
 
 
Intermediate 17 has been obtained coupling (general procedure A) intermediate 16 and 
intermediate 14, previously deprotected using procedure (C). 
 
For the deprotection reaction have been used the following reagents: 
• 8 ml HCl in dioxane anidre 
• 0.704 g intermediate 14, 1.67 mmol (1 eq) 
For the coupling reaction have been used the following reagents: 
• 0.859 g intermediate 16, 1.83 mmol (1.1 eq) 
• 0.695 g HATU, 1.83 mmol (1.1 eq) 
• 5 ml DMF 
• 1.104 ml NMM, 10.02 mmol (6 eq) 
 
The reaction have been controlled using TLC, CH2Cl2/CH3OH (90:10) and extracted with 
CH2Cl2. The crude product was purified by silica gel flash chromatography (CH2Cl2/MeOH, 
from 100 to 97:3). The intermediate was a yellow solid. The reaction yield was 28% 
 
1H NMR (300 MHz, CDCl3) δ 8.05 – 7.70 (m, 4H), 7.29 (d, J = 10.6 Hz, 5H), 6.85 (dd, J = 16.2, 8.2 Hz, 4H), 5.57 
(s, 1H), 5.08 (d, J = 17.5 Hz, 2H), 4.74 – 4.61 (m, 1H), 4.58 (t, J = 7.3 Hz, 1H), 3.64 (s, 1H), 3.49 (s, 1H), 3.35 – 2.97 
(m, 6H), 2.21 – 1.94 (m, 7H), 1.89 – 1.52 (m, 8H), 1.44 – 1.18 (m, 1H), 1.09 – 0.83 (m, 12H). 
Experimental section 
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Compound 4 
7-(diethylamino)-N-(3-((S)-4-methyl-2-(4-(4-((2S,3R)-3-methyl-1-oxo-1-(2-
(pyrrolidin-1-yl)ethylamino)pentan-2-
ylcarbamoyl)phenoxy)benzamido)pentanamido)propyl)-2-oxo-3,8a-
dihydro-2H-chromene-3-carboxamide 
 
 
 
 
Compound 4 has been obtained coupling (general procedure A) carboxy-coumarinee and 
intermediate 17, previously deprotected using procedure B. 
 
For the deprotection reaction have been used the following reagents: 
• 10.0 ml MeOH  
• 0.080 g Pd/C 
• 0.100 g intermediate 17, 0.129 mmol (1 eq) 
For the coupling reaction have been used the following reagents: 
• 0.037 g carboxy-coumarinee, 0.142 mmol (1.1 eq) 
• 0.053g HATU, 0.142 mmol (1.1 eq) 
• 1 ml DMF 
• 0.5 ml DCM 
• 0.028 ml NMM, 0.258 mmol, (2 eq) 
 
The reaction have been controlled using TLC, CH2Cl2/CH3OH (90:10) and extracted with 
CH2Cl2. The crude product have been digested with Et2O. No further purification have been 
done. The reaction yield was 83.0%. 
 
1H NMR (300 MHz, CDCl3) δ 8.93 (s, 1H), 8.06 – 7.66 (m, 4H), 7.64 – 7.31 (m, 2H), 6.97 (dd, J = 12.8, 8.7 
Hz, 4H), 6.65 (d, J = 8.9 Hz, 1H), 6.49 (s, 1H), 4.82 – 4.57 (m, 2H), 3.75 (s, 1H), 3.61 – 3.21 (m, 10H), 3.00 (d, 
J = 29.6 Hz, 7H), 2.24 – 1.49 (m, 11H), 1.38 – 1.10 (m, 6H), 0.95 (dd, J = 17.6, 10.1 Hz, 12H). 
Experimental section 
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Intermediate 18 
(S)-tert-butyl 4-methyl-1-oxo-1-(prop-2-ynylamino)pentan-2-ylcarbamate 
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Intermediate 18 has been obtained coupling (general procedure A) Boc-Leucine and 
propargylamine using the subsequent reagents: 
 
• 1.00 g BocLeuOH, 4.01 mmol (1.1 eq) 
• 0.401 g propargylamine, 7.29 mmol (2 eq) 
• 0.837 g HOBT, 5.47 mmol (1.5 eq) 
• 1.70g HBTU, 4.37 mmol (1.2 eq) 
• 10 ml DCM 
• 0.080 ml NMM, 7.3 mmol (2 eq) 
 
The reaction have been controlled using TLC, CH2Cl2/CH3OH (90:10) and extracted with 
CH2Cl2. The crude product was purified by silica gel flash chromatography (CH2Cl2/MeOH, 
from 100 to 98:2). The intermediate was a white solid. The reaction yield was 58.3%. 
 
1H NMR (300 MHz, CDCl3) δ 6.58 (s, 1H), 4.90 (s, 1H), 4.19 – 3.98 (m, 3H), 2.21 (t, J = 2.5 Hz, 1H), 1.75 – 
1.58 (m, 1H), 1.57 – 1.36 (m, 11H), 0.93 (dd, J = 6.0, 4.1 Hz, 6H). 
Experimental section 
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Intermediate 19 
4-(4-(benzyloxycarbonyl)phenoxy)benzoic acid 
 
 
 
Acid 4.4 '-ossibisbenzoico (5.00 g, 19:36 mmol) is dissolved into a flask with DMF (10 ml for 
each gram of acid), then is added TEA (3.23 ml, 23.2 mmol). Benzyl bromide (2.77 ml, 23,23 
mmol) and is added dropwise to the reaction mixture. It is than reacted for 3 hours at 60° C 
and controlled with a TLC, CH2Cl2/CH3OH (90:10). DMF is evaporated the in vacuo and the 
crude product is extracted with AcOEt, following these washes: three times with 2N HCl, 1 
time with distilled water and 1 time with a saturated solution of NaCl. The organic phase is 
evaporated in vacuo and the obtained solid is washed with CHCl3 (about 30 ml), and filtered. 
Subsequently, after that the organic phase is evaporated and the crude product is digested with 
CH2Cl2. The final product is a white solid. The reaction yield is 53%. 
 
1H NMR (300 MHz, DMSO)  12.96 (bs, 1H); 8.02 (m, 4H); 7.4 (m, 5H); 7.2 (m, 4H); 5.35 (s, 2H). 
Experimental section 
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Intermediate 20 
benzyl 4-(4-((2S,3R)-3-methyl-1-oxo-1-(2-(pyrrolidin-1-
yl)ethylamino)pentan-2-ylcarbamoyl)phenoxy)benzoate 
 
 
 
Intermediate 20 has been obtained coupling (general procedure A) intermediate 19 and 
intermediate 15, previously deprotected using procedure C. 
For the deprotection reaction have been used the following reagents: 
• 13.97 ml HCl in dioxane anidre 
• 1.397 g intermediate 15, 4.27 mmol (1 eq) 
For the coupling reaction have been used the following reagents: 
• 1.640 g intermediate 19, 4.69 mmol (1.1 eq) 
• 1.944 g HBTU, 5.12 mmol (1.2eq) 
• 5.0 ml DMF 
• 2.36 ml NMM, 21.41 mmol (5 eq) 
 
The reaction have been controlled using TLC, CH2Cl2/CH3OH (90:10) and extracted with 
CH2Cl2. The crude product have been digested with Et2O. No further purifications have been 
done. The reaction yield was 88.0%. 
 
1H NMR (300 MHz, CDCl3) δ 8.06 (dt, J = 12.8, 6.6 Hz, 4H), 7.74 (s, 1H), 7.39 (tt, J = 13.5, 7.1 Hz, 5H), 7.03 
(dt, J = 19.7, 9.8 Hz, 4H), 5.36 (s, 2H), 4.70 (dd, J = 8.7, 6.1 Hz, 1H), 3.89 – 3.69 (m, 1H), 3.50 – 3.33 (m, 1H), 
3.05 (d, J = 25.8 Hz, 6H), 2.19 – 1.96 (m, 5H), 1.64 – 1.48 (m, 1H), 1.37 – 1.18 (m, 1H), 0.98 (dq, J = 14.7, 7.4 
Hz, 6H). 
Experimental section 
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Compound 5 
N-((2S,3R)-3-methyl-1-oxo-1-(2-(pyrrolidin-1-yl)ethylamino)pentan-2-yl)-4-
(4-((S)-4-methyl-1-oxo-1-(prop-2-ynylamino)pentan-2-
ylcarbamoyl)phenoxy)benzamide 
 
 
 
Compound 5 has been obtained coupling (general procedure A) intermediate 20, previously 
deprotected using procedure B and intermediate 18, previously deprotected using procedure 
C. 
 
For the intermediate 20 deprotection reaction have been used the following reagents: 
• 51.5 ml MeOH 
• 0.412 g Pd/C 
• 0.588 g intermediate 20, 1.05 mmol (1.1 eq) 
For the intermediate 18 deprotection have been used the following reagents: 
• 2.56 ml HCl in dioxane anidre 
• 0.257 g intermediate 18, 0.96 mmol (1 eq) 
For the coupling reaction have been used the following reagents: 
• 0.437 g HBTU, 1.056 mmol (1.2 eq) 
• 5.5 ml DMF 
• 0.212 ml NMM, 1.92 mmol (2eq) 
•  
The reaction have been controlled using TLC, CH2Cl2/CH3OH (90:10) and extracted with 
CH2Cl2. The crude product was purified by silica gel flash chromatography 
(CH2Cl2/MeOH+10%NH3 from 100 to 90:10). The intermediate was a white solid. The 
reaction yield was 63.3%. 
 
1H NMR (300 MHz, CDCl3) δ 8.24 – 7.91 (m, 3H), 7.68 (dd, J = 40.8, 8.3 Hz, 4H), 6.64 (dd, J = 30.8, 8.1 Hz, 
4H), 4.88 (d, J = 6.7 Hz, 1H), 4.53 (t, J = 8.0 Hz, 1H), 4.17 – 3.85 (m, 2H), 3.80 – 3.47 (m, 2H), 3.07 (s, 6H), 
2.30 – 2.16 (m, 1H), 2.01 (s, 4H), 1.91 – 1.59 (m, 5H), 1.44 – 1.19 (m, 2H), 1.11 – 0.83 (m, 12H). 
Experimental section 
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Intermediate 21 
2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethyl 4-methylbenzenesulfonate 
 
 
 
An NaOH aqueous solution (0.69g / 4 mL) was added to a THF solution (4 mL) of 
tetraethylene glycol (21.95 g, 113 mmol) at 0 °C and then a THF solution (13 mL) of  p-
toluenesulfonyl chloride (2.08 g, 10.93 mmol) was added while stirring (1 h). After stirring at 
0 °C (2 h), the reaction mixture was poured into ice H2O (65 mL). The organic layer was 
separated, and the aqueous layer was extracted with CH2Cl2 (3 × 50 mL). The combined 
organic layers were washed twice with H2O (50 mL). The organic layer was dried (Na2SO4) 
and evaporated in vacuo to yield 3.64 g (96%) of crude product as a yellow oil. No further 
purifications have been done. 
1H NMR (300 MHz, CDCl3) δ 7.79 (d, J = 8.3 Hz, 2H), 7.33 (d, J = 8.1 Hz, 2H), 4.20 – 4.10 (m, 3H), 3.76 – 
3.50 (m, 14H), 2.43 (s, 3H). 
Experimental section 
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Intermediate 22 
2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethanol 
 
 
 
NaN3 (1.40 g, 21.55 mmol) was added to an EtOH solution (60 mL) of intermediate 21 (3.00 
g, 8.62 mmol). After stirring at 70 °C (18 h), H2O (50 mL) was added and the solvent was 
concentrated to ׽1/3 volume in vacuo. The remaining solution was extracted with EtOAc (3 × 
50 mL). The combined organic phases were dried (Na2SO4) and evaporated in vacuo, and the 
crude product purified by column chromatography (CH2Cl2/MeOH from 100 to 98:2) to yield 
(86%) of compound as a yellow oil. 
1H NMR (300 MHz, CDCl3) δ 3.80 – 3.56 (m, 14H), 3.40 (t, J = 4.4 Hz, 2H), 2.24 (s, 1H). 
Experimental section 
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Intermediate 23 
2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)acetaldehyde 
 
 
 
To an anhydrous CH2Cl2 solution (2 ml) of oxalyl chloride (0.10 ml, 1.10 mmol) maintained 
at -78°C under Argon was slowly added freshly distilled DMSO (0.19 ml, 3.29 mmol). The 
mixture was sti-rred (30 min), and then intermediate 22 (0.20 g, 0.91 mmol) was added via 
syringe. The mixture was stirred for an additional 30 min at -78°C, and then Et3N (0.78 ml, 
6.57 mmol) was added (10 min) and the mixture was stirred (15 min) at this temperature and 
warmed to ambient temperature. The reaction solution was diluted with CH2Cl2 (10 ml) and 
washed with H2O (2 x 10 ml). The organic layer was dried (Na2SO4), and evaporated under 
vacuo obtaining intermediate 23. The yield of reaction is 62%. 
1H NMR (300 MHz, CDCl3) δ 9.73 (s, 1H), 4.17 (s, 2H), 3.79 – 3.55 (m, 8H), 3.39 (t, J = 4.7 Hz, 2H), 1.45 (dt, 
J = 18.9, 7.3 Hz, 2H). 
 
Experimental section 
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Intermediate 24 
methyl 5-((3aS,4R,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)pentanoate 
 
 
SOCl2 is added dropwise to a biotin suspension in MeOH. The solution is stirred overnight at 
room temperature. The solvent is than evaporated under vacuo. No further purification have 
been done. The yield of reaction is 80% 
For the reaction have been used the following reagents: 
• 0.100 g biotin, 0.410 mmol  
• 1.0 ml MeOH 
• 0.967 ml SOCl2 
 
1H NMR (300 MHz, DMSO) δ 9.05 (s, 2H), 6.51 (d, J = 50.3 Hz, 2H), 5.86 (s, 3H), 5.38 (s, 1H), 5.11 (dd, J = 
12.0, 4.2 Hz, 1H), 5.00 – 4.71 (m, 1H), 4.59 (t, J = 6.8 Hz, 2H), 4.11 – 3.40 (m, 6H). 
Experimental section 
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Intermediate 25 
5-((3aS,4R,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)pentanehydrazide 
 
 
 
Hydrazine is added to a MeOH solution of intermediate 24. The reaction mixture is stirred at 
room temperature for 16h. The solution is concentrated and then diluted with H2O. (14.2 ml) 
The aqueous phase is washed with CHCl3 (9 ml x 3). The aqueous solution is evaporated 
under vacuum obtaining intermediate 25. The reaction yield is 71.3% 
 
For the reaction have been used the following reagents: 
• 0.084 g intermediate (24), 0.328 mmol 
• 0.720 ml MeOH 
• 0.140 ml hydrazine, 2.88 mmol 
 
1H NMR (300 MHz, DMSO) δ 8.95 (s, 1H), 6.41 (d, J = 18.9 Hz, 2H), 4.36 – 4.22 (m, 1H), 4.12 (s, 1H), 3.49 – 
3.23 (m, 1H), 3.09 (s, 1H), 2.80 (dt, J = 21.7, 10.9 Hz, 1H), 2.60 – 2.52 (m, 2H), 2.08 – 1.88 (m, 2H), 1.69 – 
1.14 (m, 6H). 
Experimental section 
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Compound 6 
(E)-N'-(2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethylidene)-5-((3aS,4R,6aR)-
2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanehydrazide 
 
 
Compound 6 has been obtained stirring overnight a solution of intermediate 23 in CH2Cl2  and 
a solution of intermediate 25 in THF/H2O (1:1) using the following reagents: 
• 0.270 g intermediate 23, 1.24 mmol (1.5 eq) 
• 1.41 ml CH2Cl2 
• 0.211 g intermediate 25, 0.82 mmol (1 eq) 
• 7.07 ml THF/H2O (1:1) 
 
The reaction have been controlled using TLC, CH2Cl2/CH3OH (90:10). The crude product 
was purified by silica gel flash chromatography (CH2Cl2/MeOH from 100 to 90:10). The 
intermediate was a white solid. The reaction yield was 50%. 
 
1H NMR (300 MHz, D2O) δ 7.52 (s, 1H), 7.42 – 7.34 (m, 1H), 4.61 – 4.48 (m, 1H), 4.39 (d, J = 4.3 Hz, 1H), 
4.21 (d, J = 4.5 Hz, 2H), 3.67 (s, 12H), 3.45 (d, J = 4.8 Hz, 2H), 3.35 – 3.22 (m, 1H), 2.95 (dd, J = 13.1, 4.7 Hz, 
1H), 2.73 (d, J = 12.9 Hz, 1H), 2.28 (t, J = 7.2 Hz, 2H), 1.50 (dd, J = 62.4, 19.4 Hz, 6H). 
Experimental section 
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Compound 7 
N-((S)-4-methyl-1-oxo-1-(1-((E)-14-oxo-18-((3aR,4S,6aS)-2-oxohexahydro-
1H-thieno[3,4-d]imidazol-4-yl)-3,6,9-trioxa-12,13-diazaoctadec-11-enyl)-1H-
1,2,3-triazol-4-ylamino)pentan-2-yl)-4-(4-((2S,3R)-3-methyl-1-oxo-1-(2-
(pyrrolidin-1-yl)ethylamino)pentan-2-ylcarbamoyl)phenoxy)benzamide 
 
 
A solution (5 mM) of compound 6 in 5%CH3CN / HEPES is added to a solution (25μM) of 
compound 5. Then CuBr is added and the reaction mixture is stirred at room temperature for 
1h.  
The final compound has been analyzed through a direct infusion analysis using an ESI- triple- 
quadrupole.   
Experimental section 
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Compound 8 
N-((S)-4-methyl-1-oxo-1-(1-(2-oxo-7,10,13-trioxa-3,4-diazapentadecan-15-
yl)-1H-1,2,3-triazol-4-ylamino)pentan-2-yl)-4-(4-((2S,3R)-3-methyl-1-oxo-1-
(2-(pyrrolidin-1-yl)ethylamino)pentan-2-ylcarbamoyl)phenoxy)benzamide 
 
 
 
Compound (8) has been synthesized following general procedure F, G, H, described in 
“general procedure for proteomic reactions”, using the following reagents: 
 
• 0.025 mM solution of compound 5 in HEPES 50 mM 
• 5.0 mM solution of compound 6 in 5%CH3CN/HEPES 50 mM 
• 0.2 mg CuBr, 0.0014 mmol 
• 0.78 mg acetyldrazide, 0.010 mmol 
• 0.123 mg p-anisidine, 0.001 mmol 
 
The final compound has been analyzed through a direct infusion analysis using an ESI- triple- 
quadrupole.   
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8 Introduction 
 
 
8.1 Biomarker discovery 
A biomarker is a measurable indicator of a specific biological state, particularly one relevant 
to the risk of contraction, the presence or the stage of disease. 
Better biomarkers are urgently needed to improve diagnosis, guide molecularly targeted 
therapy and monitor activity and therapeutic response across a wide spectrum of disease. 
Proteomics methods based on mass spectrometry hold special promise for the discovery of 
new biomarkers that might form the foundation for new clinical blood tests, but to date 
their contribution to the diagnostic armamentarium has been disappointing. 
Biomarkers can be used clinically to screen for diagnose or monitor the activity of diseases, 
guide molecularly targeted therapy or assess therapeutic response. 
The utility and importance of biomarkers has been recognized by substantial public and 
private funding, and biomarker discovery efforts are now commonplace in both academic and 
industrial settings. 
The principal enabling technology of proteomic discovery is MS. All mass spectrometers, 
regardless of type, ionization mode or performance characteristics, produce mass spectra, 
which plot the mass-to-charge ratio of the ions observed (x-axis) versus detected ion 
abundance (y axis)62.  
The typical proteomics experiment consists of five stages. In stage 1, the proteins to be 
analysed are isolated from cell lysate or tissues by biochemical fractionation or affinity 
selection. 
This often includes a final step of one-dimensional gel electrophoresis, and defines the ‘sub-
proteome’ to be analysed. MS of whole proteins is less sensitive than peptide MS and the 
mass of the intact protein by itself is insufficient for identification. Therefore, proteins are 
degraded enzymatically to peptides in stage 2, usually by trypsin, leading to peptides with C-
terminally protonated amino acids, providing an advantage in subsequent peptide sequencing. 
In stage 3, the peptides are separated by one or more steps of high-pressure liquid 
chromatography in very fine capillaries and eluted into an electrospray ion source where they 
are nebulized in small highly charged droplets. After evaporation, multiple protonated 
peptides enter the mass spectrometer and, in stage 4, a mass spectrum of the peptides eluting 
at this point is taken (MS1 spectrum, or ‘normal mass spectrum’). The computer generates a 
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prioritized list of these peptides for fragmentation and a series of tandem mass spectrometric 
or ‘MS/MS’ experiments ensues (stage 5). These consist of isolation of a given peptide ion, 
fragmentation by energetic collision with gas, and recording of the tandem or 
MS/MS spectrum. The MS and MS/MS spectra are typically acquired for about one second 
each and stored for matching against protein sequence databases. The outcome of the 
experiment is the identification of the peptides and therefore the proteins making up the 
purified protein population63 (Figure 11). 
 
 
 
Figure 11  
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8.2 Oxidative stress 
 
The term oxidative stress defines an alteration of the basal red ox balance in favour of the 
oxidation reactions. This impairment could be triggered by endogenous and/or exogenous 
factors, and is the result of an increase of the concentration of pro-oxidant species or the 
depletion of the endogenous antioxidants64. 
The direct consequence of the oxidative stress is a widespread oxidation of biological 
substrates (DNA, proteins, lipids and sugars), through nonphysiological reaction mechanisms. 
The extent and the reversibility of the molecular damages, the adaptation capability of the 
biological system involved and the rate of the defensive response are the main factors which 
lead up to a restore of the physiological condition or the development of a dysfunction64. The 
main molecular mediators of oxidative stress are the reactive oxygen species (ROS), which 
are generated in cells by both enzymatic and nonenzymatic sources65, 66. The ROS are 
essentially radicals and are characterized by unpaired electrons, which are responsible of the 
high reactivity of these compounds towards any type of substrate. ROS are produced 
physiologically at small concentration and are implicated in a multitude of physiological 
processes including ageing and cell mediated immune response. 
A massive increase of the basal levels of oxidative stress has been associated in the genesis 
and/or progression of many chronic and degenerative cardiovascular diseases and in many 
metabolic disorders like diabetes, atherosclerosis, hypertension, ischemia/reperfusion 
damages but also in many neurodegenerative diseases such as Alzheimer’s disease (AD), 
amyotrophic lateral sclerosis (ALS), and Parkinson’s disease (PD)64, 67-70. 
However, it is still unclear whether the oxidative stress is the primary cause and directly 
contributes to the development of these pathologies, or it is only the result of the tissues 
degeneration, which characterize the progression of these diseases. Anyway, it represents a 
valid pharmacological target when the corresponding redox imbalance is still reversible. This, 
however, requires detailed knowledge on the biochemical mechanisms involved. 
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8.3 Carbonyl stress 
 
Oxidative decomposition of polyunsaturated fatty acids (PUFAs) and sugars initiates chain 
reactions lead to the formation of a variety of molecules of three to nine carbon atoms, 
characterized by one or more carbonyl functions.  
These products, named as reactive carbonyl species (RCS), are characterized by a strong 
electrophilicity and can react with nucleophilic endogenous substrates such as DNA or 
proteins, forming irreversible covalent adducts called advanced lipoxidation end-products 
(ALEs) and advanced glycation end-products (AGEs). The overall reaction is named 
carbonylation. Miyata was the first to define as ‘‘carbonyl stress’’ the accumulation in serum 
of RCS derived from lipids and carbohydrates and the subsequent massive proteins 
carbonylation71. Compared to free radicals and ROS, lipid and sugar-derived RCS have a 
longer half-life. Furthermore, while ROS are mainly radical and/or ionic species, these 
compounds are neutral molecules, with LogP values ideal to permeate cellular membranes 
and diffuse within or even escape from the cell to react with targets far from the site of 
formation. Therefore, these soluble reactive intermediates, precursors of ALEs, are not only 
cytotoxic, but they also behave as mediators and propagators of oxidative stress and tissue 
damage, acting as second messengers. 
RCS could be classified by considering the chemical structure and their reactivity. The most 
reactive and cytotoxic RCS are α,β-unsaturated aldehydes [4-hydroxy-trans-2-nonenal (HNE) 
and acrolein (ACR)], dialdehydes [malondialdehyde (MDA) and glyoxal (GO)], keto-
aldehydes [4-oxo-trans-2-nonenal (ONE) and isoketals (IsoK)]. 
Other less reactive compounds are 2-Hydroxyheptanal, product to lipid peroxidation of ω-6 
PUFAs (linoleic acid, arachidonic acid) and 2-Hydroxyalkanales with 8, 9, 10, and 11 C-
atoms, generated from hydroperoxides of oleic acid72. 
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8.4 Reactive Carbonyl Species (RCS) 
 
One mechanism of free radical-mediated damage occurs through initiation events such as 
lipid peroxidation and is particularly interesting for researchers in applied toxicology, as 
protein 
carbonylation via toxic reactive aldehydes is known to result in altered protein function. The 
generation of free radicals in close proximity to lipid rich cellular membranes containing 
PUFAs initiates lipid peroxidation occurs when HO• and ONOO_ abstract an allylic hydrogen 
from PUFAs. The initial step of this process demonstrates the basic principle that 
reaction of a radical (HO• and ONOO_) with a nonradical species typically results in the 
generation of a new, less reactive radical, which, in this case, is a carbon-centered lipid radical 
(L•) (Figure 12). 
 
Figure 12: Lipid peroxidation 
 
This L•, in turn, reacts with molecular oxygen to yield a lipid peroxyl radical (LOO•), 
resulting in the formation of lipid hydroperoxide (LOOH). These LOOHs react with trace 
metals to form lipid alkoxyl radicals (LO•). Both LO• and LOO• radicals generate reactive 
R,β-unsaturated aldehydes through cyclization and/or β-scission and degradation, most 
commonly generating highly electrophilic products such as 4-hydroxynonenal (4-HNE), 
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malondialdehyde (MDA), and acrolein (ACR). As defined, these reactive aldehyde species 
result from free radical-initiated lipid peroxidation and are fairly 
long-lived within the cell, persisting for up to 2 min, allowing for intracellular diffusion and 
covalent modification of DNA, lipid, and protein throughout the cell. The mobility and 
reactivity of these products of lipid peroxidation are central to their involvement in altered 
cellular signaling and diseases of oxidative stress. 
 
8.4.1 α,β-Unsaturated Aldehydes 
 
(HNE) 4-Hydroxy-trans-2-Nonenal 
HNE (Figure 13) is the most abundant and toxic α,β-unsaturated aldehyde, generated through 
the β-cleavage of hydroperoxides from ω-6 PUFAs which also plays a role in a variety of 
physiopathological processes73-76. HNE is known to exert a wide range of biological activities, 
among these, inhibition of protein and DNA synthesis, inactivation of enzymes, stimulation of 
phospholipase C, induction of cyclooxygenase 2, reduction of gap-junction communication, 
stimulation of neutrophil chemotaxis and modulation of platelet aggregation73, 75, 77-80. 
 
  
 
Figure 13: Molecular formulas of the main RCS produced during oxidation of 
lipids and sugars 
 
Furthermore, HNE modulates the expression of various genes and the cell signal transduction, 
is involved in the oxidative stress-induced apoptosis activating the caspase cascade80-83, 
furthermore is also a potent mutagen agent84, 85 and has been reported to inactivate several 
enzymes73, 86-109. HNE reacts with cellular nucleophiles, in particular sulfhydryl groups of 
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proteins or peptides such as glutathione (GSH), via 1,2- and 1,4-Michael addition and the 
thioether adducts further undergo cyclization (fig 2) to form cyclic hemiacetals73, 75, 77. 
The high rate constant for the reaction of GSH with HNE indicates a half-life of 
approximately 2 min in the presence of physiological concentrations of GSH (5 mM). HNE 
reacts also with the imidazole moiety of His residues110 and with the ε-amino group of Lys 
residues to form Michael adducts, which further undergo cyclization between the aldehyde 
moiety and the C-4 position of HNE to form a hemiacetal structure111, 112. Alternatively, HNE 
reacts with the ε-amino group of Lys (1,2-addition) forming a carbinolamine intermediate that 
rearranges and loses water to produce a Schiff base, which can eventually lead to the 
formation of a 2-pentylpirrole derivative (Figure 14) through an enammine intermediate113.  
The di-functional nature of HNE (electrophilic C-3 and carbonyl group) makes it able to form 
intra- and inter-molecular protein cross-links through Michael addition at C-3 followed by 
Schiff base formation114.  
 
 
 
Figure 14: Chemical structures of HNE-cysteine, HNE-histidine and HNE-lysine 
 
(ACR) Acrolein 
 
ACR (Figure 13) is not only a lipoxidation product, but it is also produced during the 
myeloperoxidase-catalyzed metabolism of hydroxy-amino acids. For this reason, some data 
suggest that phagocyte-mediated formation of ACR may be of central importance in 
promoting tissue injury at sites of inflammation115. 
ACR can be generated from the oxidative deamination of spermine and spermidine catalyzed 
by polyamine oxidase, that is an ubiquitous pollutant in the environment (a by-product of 
overheating organic matter) and is a main component of the gas phase of cigarette smoke (25–
140 mg/cigarette)116, 117. 
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ACR is the strongest electrophilic α,β-unsaturated aldehyde, showing the highest reactivity 
with thiols and amines (ACR reacts more than 100 times faster with GSH than HNE). The 
mechanism of reaction with GSH and protein thiol groups is the same of HNE, without the 
cyclization rearrangement. The thiol adducts of ACR are considerably more stable than those 
formed by all other α,β- unsaturated aldehydes dissociation constants for ACR adducts being 
10–10,000 times lower75. 
Like HNE, ACR reacts preferentially with Cys, Lys, and His residues. The Lys can reacts 
with more than one acrolein molecules to form a Nε-(3-formyl-3,4- dehydropiperidino)-lysine 
(FDP-Lys) and Nε-(3-methylpyridinium)-lysine (MPLys)117, 118. 
FDP-Lys is not a stable end-product, but a reactive intermediate that covalently binds to 
thiols, suggesting a new mechanism of protein thiolation in which the FDP-Lys, generated in 
the ACR-modified protein, reacts with sulfhydryl groups to form thioether adducts119. 
Like HNE, ACR inhibits many enzyme systems and cell proliferation86-89, 119-123. The 
mechanism of such effects may be related to the ability of ACR to deplete cellular thiols 
and/or to induce gene activation, either directly or following interaction with transcription 
factors, particularly the red ox-regulated124. 
The acute effects of ACR have been extensively investigated in several experimental models, 
such as rat aortic rings125. ACR is a powerful respiratory tract irritant and instigates asthma-
like symptoms during inhalation, causing consequent pulmonary edema and respiratory 
distress126. 
 
8.4.2 Keto-Aldehydes 
 
4-oxo-trans-2-Nonenal (ONE) 
 
4-oxo-trans-2-nonenal (ONE), the two electron oxidation product of HNE (Figure 13), is an 
end product of lipoxidation of ω-6 PUFAs127, 128. ONE contains a keto group at C4 position 
that makes the compound more reactive towards nucleophils than HNE (e.g., at 3–10 mM, 
ONE is more neurotoxic than HNE)129. Unfortunately, because 4-ONE has only recently been 
recognized as a potentially pathogenic compound, estimates regarding its intracellular 
concentrations are lacking, even if it has been detected in human plasma as ascorbyl 
conjugate80. The predominant initial reaction of ONE with nucleophilic sites in proteins 
appears to involve Michael addition to the central ONE double bond, more at C3 than at C2, 
to give substituted 4-oxononanals 130, 131. 
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This adducts may then condensate with the Nε-amino group of Lys to form substituted 
pyrrole cross-links. Unlike HNE, ONE was found to modify also peptides containing Arg 
residues (in addition to His, Lys, Cys) to give stable, covalent adducts. While the order of 
potency for amino acid adduction is similar for HNE and ONE (Cys, His, Lys, Arg), the 
difference in absolute potency (i.e., rate constants) between the two aldehydes is remarkable, 
because ONE is much more reactive than HNE towards thiols and amines. 
 
8.4.3 Di-Aldehydes 
 
(MDA) Malondialdehyde 
 
MDA (Figure 13) precursors are mainly arachidonic acid (20:4) and docosahexaenoic acid 
(22:6), it cannot be considered a highly reactive compound under physiological conditions, 
because the main species existing in aqueous solution at pH 7.4 is the enolate anion, stabilized 
by a conjugated π-bond system. 
Resonance stabilization reduces the electrophilicity of MDA, decreasing its reactivity with 
protein amine groups such as Lys and Arg. At lower pH, when the β-hydroxyacrolein 
becomes the predominant species, its reactivity is significantly increased. This makes the 
molecule able to react with nucleophiles in a Michael type 1,4-addition reaction, similarly to 
other α,β-unsaturated aldehydes, such as HNE or ACR. Resonance stabilization of the 
intermediate anion favours this reaction, which results in the formation of a β-substituted 
acrolein as end-products. 
At least 80% MDA in tissues is bound reversibly to proteins in vivo. Lys and Arg are the only 
amino acids whose side-chains react with MDA to form the semi-stable Nε-β-lysyl-amino-
acrolein (β-LAA) and the stable Nδ-(2-pyrimidyl)-L-ornithine (NPO)132, 133. 
 
 (GO) Glyoxal 
 
GO (Figure 13) is an α-ketoaldehyde intermediate formed by oxidative degradation of 
glucose and degradation of glycated proteins, by ascorbate autoxidation, and by peroxidation 
of lipids134, 135 and is indeed formed during UV irradiation of PUFAs and autoxidation of 
arachidonic acid. 
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Figure 15: Chemical structures of MDA-Lys adducts and cross-links 
 
GO reacts with the free amino groups of proteins to give Schiff’s bases (by the non-enzymatic 
reaction of glycation), which undergo rearrangement to form relatively stable ketoamines 
(Amadori products). The glycated proteins undergo further dehydration, cyclization, oxidation 
and rearrangement to generate advanced glycation end-products (AGEs). GO reacts with Cys 
and Lys to form the EAGLE oxidative adduct, Nε-(carboxymethyl)-lysine (CML) and 
(carboxymethyl)-cysteine (CMC). 
 
 
Figure 16: Chemical structures of GO adducts and cross-link 
 
The ability of GO to cross-link proteins has widely been reported and elevated levels of this 
products have been measured in serum of uremic and haemodialysis patients111, 136. 
However, many of the GO cross-links likely occurring in vivo remains uncharacterized, 
because the molecular mechanisms of the cross linking reaction needs to be fully elucidated. 
GO has been demonstrated to induce mutagenesis in several cellular models, an effect that is 
inhibited by thiol compounds137, 138. 
 
1.4 Protein oxidation and carbonylation 
Emerging evidence indicates that ROS can cause specific protein modifications that may lead 
to a change in the activity or function of the oxidized protein. 
Several major forms of oxidative modifications occur on amino acid residue side chains, 
including new chemical moieties such as hydroxy or carbonyl group. 
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Oxidation of proteins is irreversible and irreparable and may alter the conformation of the 
polypeptide chain, determining the partial or total inactivation of proteins64, 70, 139-141. 
The consequent loss of function or structural integrity of modified proteins can have a wide 
range of downstream functional consequences and may be the cause of subsequent cellular 
dysfunctions and tissue damages. The introduction of carbonyl moieties into proteins may 
arise from a direct oxidation of amino acid side-chains, resulting in the formation of 2-
pyrrolidone (Pro oxidation), glutamic semialdehyde (Arg and Pro oxidation), α-aminoadipic 
semialdehyde (Lys oxidation), and 2-amino-3-ketobutyric acid from (Thr oxidation). 
Protein carbonyl derivatives can also be generated through oxidative cleavage of proteins, 
through the α-amidation pathway or through oxidation of glutamine side chains, leading to 
the formation of a peptide in which the N-terminal amino acid is blocked by an α-ketoacyl 
derivative (Figure 17).  
 
 
Figure 17: Generation of protein carbonyls through direct oxidation of Lys, Arg 
and Pro residues 
 
The second mechanism to include carbonyl moieties in protein is the reaction of the 
nucleophilic side chains of Cys, His, and Lys residues with glucid and lipid-derived reactive 
carbonyl species (RCS) to generate AGEs and ALEs77, 142, 143. 
Furthermore, carbonyls are produced during oxidation of glycated proteins. Glycation is a 
spontaneous reaction recognized as the initial step of a very complex process, the Maillard 
cascade, which involves the formation of several end-stage products responsible for protein 
modification and is catalyzed by oxidative stress and ROS. Complex interactions between 
oxidation and glycation (the glycoxidation process) are considered to play a key role in 
protein modification144-146. 
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8.5 Protein carbonyls in cardiovascular diseases and 
neurodegeneration. 
 
Protein modification by lipoxidation-derived RCS is little known, although numerous 
evidences indicate their involvement in physiological ageing and in the onset and/or 
progression of several diseases such as cardiovascular (e.g., atherosclerosis, long-term 
complications of diabetes) and neurodegenerative diseases (e.g., AD, PD), cerebral ischemia, 
rheumatoid arthritis, and post-ischemic reperfusion injury73, 78, 147, 148. The increased protein 
carbonylation by lipids and carbohydrates in chronic diseases is the result of carbonyl 
overload on metabolic pathways involved in detoxification of RCS145, 149. This leads to a 
general increase in steady-state levels of RCS formed by both oxidative and non-oxidative 
reactions. In fact, in both diabetes and uraemia, not only glycoxidation and lipoxidation 
products are increased, but also the products of reaction of proteins with dicarbonyl 
compounds formed by non-oxidative mechanisms150. 
By reacting with nucleophilic sites in proteins, RCS generate typical ALEs such as MDA-Lys 
(Schiff base adduct), HNE-Lys (Michael adduct), HNE-Lys (pyrrole derivative) and FDP-Lys 
[Nε-(3-formyl-3,4 dehydropiperidino)-lysine]. 
These adducts have been detected in oxidized lipoproteins and/or atherosclerotic lesions of 
varying severity from human aorta by immunohistochemical or chemical assays146, 148, 151-153. 
The clinical relevance of the reaction between MDA and proteins is highlighted in 
atherosclerosis. 
MDA-LDL, in addition to oxidized LDL, mediates several pro-inflammatory and pro-
atherogenic processes, which ultimately lead to foam cell generation154. MDA plasma 
concentration is increased in diabetes mellitus and MDA is found in the atherosclerotic 
plaques promoted by diabetes155. 
Adducts of apolipoprotein B-100 Lys residues with MDA and HNE and of apolipoprotein A-
1 with ACR, have been extensively characterized in human atherosclerotic lesions156, 157. 
Protein-ACR adducts have been found to be significantly elevated in serum of end-stage renal 
disease patients receiving haemodialysis and in AD158, 159. 
Carbonyl stress has been implicated in cardiac reperfusion injury, since the reperfusion-
induced mitochondrial dysfunction is mediated in part by specific mitochondrial proteins 
modified by RCS160, 161. Unsaturated aldehyde levels were found to be consistently elevated in 
plasma of patients with congestive heart failure, associated with impairment of left ventricular 
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contractility162. Lipid-derived RCS are massively involved in hyperglycaemia and in 
development of complications in diabetes150. 
Increased plasma levels of free RCS or RCS adducts have been measured in patients with 
chronic kidney failure and in long-term complications associated to haemodialysis, such as 
dialysis-related amiloydosis, and in uremic subjects97, 163-165. Protein-ACR adducts, in addition 
to MDA-Lys and HNE-protein adducts, have been also detected in glomerular lesions from 
patients with diabetic nephropathy and  in kidney (especially in the glomerular epithelial 
cells) from patients with congenital nephritic syndrome, a human model disease of 
proteinuria166, 167. 
The inter- and intra-molecular cross-linking of collagen by MDA (formation of pyridyl 
crosslinks), and the resultant modification of collagen properties and cell-matrix interactions, 
are particularly relevant in the late complications of diabetes mellitus, contributing to the 
stiffening of the cardiovascular tissue155. 
In addition, significant higher levels of HNE-modified albumin were detected in serum of 
type 2 diabetes mellitus outpatients than in the matched nondiabetics168. 
Therefore, lipid peroxidation and the consequent lipoxidative modification of proteins play a 
key role in the development of cardiovascular and kidney diseases in diabetes. 
The involvement of toxic RCS as products and propagators of oxidative damage in 
neurodegenerative diseases, mainly in AD, was elucidated in several experiments169-171. 
Elevated levels of carbonyl species have been determined in plasma and in different brain 
regions of AD patients, HNE is elevated in plasma and in cerebrospinal fluid, whereas ACR 
in the amygdala and hippocampus/ parahippocampal gyrus172-175. MDA accumulation has 
been detected immunohistochemically in the cytoplasm of astrocytes and neurons in both 
normal ageing and AD and the extent of deposition is similar in both conditions176. Increased 
concentrations of MDA (in plasma and serum) and HNE (in plasma and cerebrospinal fluid) 
have been reported in PD patients177.  
HNE levels are significantly elevated also in the sera and spinal fluid of ALS patients and 
positively correlate with the extent of the disease but not with the rate of progression, 
suggesting HNE as a possible biomarker of the disease178. 
The residual aldehyde group in some ALEs (Schiff’s base and Michael’s adducts) can further 
react to give protein cross-links and fluorescent products that are very similar to AGEs. 
Lipofuscin, the non degradable intralysosomal fluorescent pigment that accumulates with age 
in post-mitotic cells, is a recognized hallmark of ageing occurring with a rate inversely related 
to longevity. Since its formation proceeds through iron-catalyzed oxidation/polymerization of 
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protein and lipid residues, lipofuscin is now also considered the residual debris from 
lipoxidation reactions179. 
Other important toxic products formed during non-enzymatic modification and cross-linking 
or proteins in ageing and diseases are referred to as ‘‘either advanced glycation or 
lipoxidation end-products’’ (EAGLEs), Nε-(carboxymethyl)-lysine (CML) and Nε-
(carboxyethyl)-lysine (CEL) are, the major EAGLE modifications that have been measured in 
tissue proteins146, 151, 152. 
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8.6 Determination of RCS in biological matrixes 
 
Based on growing evidence of RCS role as causative/effective factors in CVD, an accurate 
and sensitive method to measure RCS in biological matrices is strictly required. 
The aim is not only to better understand the pathogenetic role of RCS and to characterize a 
biomarker of the onset and progression of the disease, but also to identify a tool for evaluating 
the efficacy of the RCS sequestering agents, a new class of compounds designed to 
prevent/retard the carbonyl related diseases. 
From an analytical point of view, RCS analysis in biological matrices can be carried out 
through two different approaches: a direct way, by measuring free aldehydes, and an indirect 
approach, based on identifying the corresponding adducts with reactive and nucleophilic 
macromolecules and peptides. Since the pioneering work of Esterbauer and his colleagues on 
HNE measurement in biological matrices by HPLC analysis180 several progress have been 
made, although the golden method is far to be reached. Measurement of the free form of HNE 
in plasma samples has been reported by using various analytical methods, developed by 
applying different techniques such as HPLC181, GCMS182 and immunoassays183. However, 
HNE is highly unstable in plasma, and only a minor fraction is detected as free form. 
Accordingly, Salomon184 found that the highest levels reported of free HNE (about 0.7 
nmol/mL for normal healthy individuals) accounted only about 10% of the levels of HNE-
protein adducts, determined as HNE-pyrrole epitopes in the blood of healthy individuals. 
The short half-life of RCS in the biological matrix is due to the high reactivity of these 
electrophilic species towards nucleophilic macromolecules and due to phase I and II 
detoxification processes76. 
Hence, it is quite clear that the direct analytical approach only allows quantitating a minor 
fraction of the free aldehyde, which is greatly affected by several variables such as 
metabolism and reaction with nucleophilic substrates. One of the main fate of carbonyls in 
biological matrices is represented by the adduction to the reactive sites of proteins, forming 
the corresponding carbonylated adducts which, being relatively stable, can undergo 
accumulation and hence can represent a suitable biomarker of carbonyls formation as well as 
protein carbonylation damage185. 
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8.7 Carbonylated proteins as biomarkers of carbonyl 
stress  
 
The amount of protein carbonylation is still determined by two main techniques, 
immunological and spectroscopic. When the analytical essay is applied directly to the sample 
it is possible to obtain a global index of carbonylation186. Although this approach permitted  to 
evaluate a significant increase of carbonylation protein in patients with oxidative damage (as 
in hemodialysis patients with chronic kidney disease187, 188), it is nevertheless limited because 
it provides only a general index and non-specific damage by carbonylation. In particular, the 
approach does not allow a distinction between direct carbonylation, for oxidative reaction, 
and carbonylation induced by a mechanism mediated by electrophilic carbonyl adduction, and 
in this case between aldehydes arising from damage induced by lipid peroxidation or other 
oxidative pathways as the autoxidation of sugars. Finally, this technique is not suitable for 
accurate quantitative analysis, a fundamental characteristic for the identification and 
validation of biomarkers. Recently, the analytical techniques described above were applied 
after protein separation, using 1D or 2D electrophoretic techniques, in order to identify the 
target protein involved in the carbonyl process. This approach has greatly improved the 
knowledge about the carbonylation protein targets, allowing a greater understanding of the 
biochemical mechanisms involved in the carbonylation damage. The technique does not allow 
however to identify the carbonylation mechanisms and in particular the main carbonyl species 
responsible for the carbonylation process. 
Therefore, it is evident that it is a priority to develop an analytical method able not only to 
identify the target protein of the carbonylation process, but also the structure of the 
modification in order to better understand the carbonylation mechanism. The analytical 
approach should also include the quantitative aspect. 
Multiple proteomic approaches indicate HSA as the main target of carbonylation in the 
serum188, 189. HSA could be carbonilated through different mechanisms, such as oxidative 
reactions due to reactive oxygen species (ROS) or covalent adduction induced by electrophilic 
compounds such as HNE and ACR64. The proteomic analysis and mass spectrometry (MS)185, 
190, 191 have demonstrated that HSA represents a highly reactive target for RCS in plasma. For 
this reason, it is a primary endogenous target to the RCS. The high reactivity of HSA against 
RCS is due to the different nucleophilic accessible sites, in particular the Cys34, followed by 
His146 and Lys199185, 191. 
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8.8 Oxidative stress in hepatic resection (hepatectomy) 
In many liver surgery is required the maintenance of the liver in a condition of ischemia that 
can be prolonged from 15 to 50 minutes. Although the development of surgical techniques 
has allowed a significant reduction of the ischemic period, the liver modifications resulting 
from partial hepatectomy interventions are still frequent192. Similarly, during the various 
stages of liver transplantation, the liver is exposed to prolonged periods of ischemia which can 
cause failure or temporary liver malfunction193-195.  It is generally known that the liver damage 
resulting from partial hepatectomy or transplantation is caused by alterations that are 
produced during the ischemic period and the subsequent reperfusion195. The lack of oxygen 
during the ischemic phase determines the de-energization of mitochondria and the reduction 
in the content of intracellular ATP. This cause the alterations Na+, H+ and Ca2 + 196-199. The 
reintroduction of oxygen, during reperfusion, is instead responsible for an incremented 
production by the mitochondria of reactive oxygen species (ROS) that induce oxidative stress 
and mitochondrial permeability transition200. 
During the phase of reperfusion occurs also the activation of Kupffer cells with the 
consequent release of ROS, nitric oxide (NO) and pro-inflammatory cytokines, such as TNF, 
IL-6, IL-1beta, MCP-1, IL- 12, IL-18 and CXC201 and inhibition of the synthesis of anti-
inflammatory cytokines (IL-10)202. 
The liver resection, and in particular the condition of ischemia and reperfusion associated 
with, therefore represents a condition of oxidative stress by now consolidated. Furthermore, 
the possibility to perform blood samples before, during and after the condition of ischemia 
and reperfusion, allows to monitor the onset of oxidative process compared to the baseline 
condition, the pre-ischemic. 
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9. Purpose of research 
One of the most exciting areas of proteomic research is the identification and validation of 
disease biomarkers which can be used as measurements within clinical studies and for the 
purpose of predictive diagnosis. The study of proteomics is considered to be a key for the 
characterization of human diseases and disease states, and mass spectrometry technology 
plays a crucial role in this disease research. 
We focused in particular on detection and quantization of post-translational modifications of 
proteins caused by oxidative and carbonyl stress. While the development of specific 
antibodies against modified proteins has made it possible to confirm the occurrence of 
oxidative stress in vivo and its involvement in several physio-pathological conditions, the 
resultant chemical modifications of proteins has not yet been explored. Proteomic tools, can 
sensitively detect oxidative damage on peptides and proteins: these tools would be helpful to 
understand exactly when, how, and where the damage occurs, and to gain deeper insights into 
the mechanism of onset, progression, and/or complication of the diseases. 
Proteomics approaches have led to the identification of the protein/s showing high sensitivity 
to oxidation/carbonylation, and among them human serum albumin (HSA) was found to be 
the main target in the circulation.  
The purpose of research of this second part of my PhD thesis was the investigation and 
validation of disease biomarkers in order to predict and monitor carbonyl stress under 
different pathological condition such as cardiovascular disease, neurodegenerative disease, 
cerebral ischemia, ischemia reperfusion. 
In particular, the overall work can be divided into two main parts: 
1. Tuning up of a mass spectrometric approach based on a triple quadrupole mass 
spectrometer in precursor and product ion scan mode in order to identify unknown 
modifications of HSA Cys 34. 
2. Tuning up of a mass spectrometric approach based on a triple quadrupole mass 
spectrometer in precursor and product ion scan mode in order to identify unknown 
modifications of HSA His 146. 
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10. Experimental section 
10.1 Materials and methods 
The diethylacetal derivative of 4-hydroxy-trans-2-nonenal (HNE-DEA) was prepared as 
reported by Rees (Rees et al., 1995). The 4-hydroxy-trans-2-nonenal (HNE) was prepared by  
hydrolysis of  HNE-DEA in 1 mM HCl for one hour, at room temperature and protected from 
light. The titration HNE was determined by UV spectrophotometric analysis (λmax 224 nm; ε 
13,750 M-1 cm-1).  
Acrolein (ACR), crotonaldehyde (CRO), glyoxal (GO), methylglyoxal (MGO), 4-hydroxy-2-
hexenal (HHE) and nonenal (NONE) were purchased from Fluka Company (Buchs, 
Switzerland). The MDA was prepared by hydrolysis of MDA bis (diethyl acetal) (Sigma-
Aldrich, Milan, Italy). 
The peptide LQQCPF was obtained by synthesis, with purity greater than 95% (Sigma-
Aldrich, Milan, Italy). The isotope deuterated peptide (LQQCPF-D8) was prepared by solid 
phase synthesis with L-phenyl-alanine-2,3,3-D5-D3-N-FMOC (CDN isotopes; Chemical 
Research 2000 Srl, Rome, Italy), with purity greater than 95%. 
The peptide HPYFYAPELLFFAK  was obtained by solid phase synthesis, with purity greater 
than 99%  in Professor Romeo’s laboratory (Università degli Studi di Milano, Milan, Italy) 
The human serum albumin (HSA), the iodoacetamide and the (±)-threo-1 ,4-dimercapto-2 ,3-
butanediol (DTT) were purchased from Sigma-Aldrich (Milan, Italy). The modified trypsin 
for peptide mapping has been provided by Promega (Milan, Italy) and chymotrypsin by 
Roche Diagnostics SpA (Monza, Italy). 
The organic solvents of analytical purity and for HPLC were purchased from Sigma-Aldrich 
(Milan, Italy). The water for HPLC was prepared with a purification system Milli-Q 
(Millipore, Bedford, MA, USA). The compound 2,2 '-azobis (2-amidinopropano) 
dihydrochloride (AAPH) was purchased from Wako (Italian Society of Chemistry, Rome, 
Italy). 
Experimental section 
      111 
 
10.2 Samples preparation and analytical methods 
 
¾ HPYFYAPELLFFAK solid phase synthesis  
The peptide HPYFYAPELLFFAK was synthesized using the following procedure: 
1. Resin swelling:  
Suspend the resin in a solution of NMP (1 ml per 150 mol of resin) and DCM (7.5 
mL) and sonicate for 5 minutes. Transfer to a reactor the swollen resin and filter under 
vacuum to obtain the dry resin. 
2. Introduction the first amino acid 
Dissolve Fmoc-aa (150 mmol, 1equivalente) in DCM/NMP (2:1) and basify with 
DIEA (2eq). Suspend the resin in the solution and leave the reactor under stirring for 
50 minutes, at the end add 400 μl of MeOH for the capping of the functional groups 
still free on the resin and stir for another 5 minutes. Once the reaction is finished, filter 
and wash 6 times with DMF. 
3. Fmoc cleavage 
Add to the resin a solution of Pip (20% in DMF) and stir for 5 minutes. Filter the resin 
and repeat the operation by increasing the stirring time to 15 minutes. Once the 
reaction is finished, filter and wash 6 times with DMF.  
4. Coupling 
Dissolve the Fmoc-aa (3 equivalents) in a solution of TBTU/HOBt (0.45 M in DMF, 4 
equivalents) and subsequently basify with DIEA (8 equivalents). Add the solution into 
the reactor containing the resin and leave the suspension under stirring for 50 minutes. 
At the end of the coupling, if necessary proceed with the insertion of a new amino 
acid, repeat the procedure for the removal of the Fmoc group, followed by the new 
coupling, and proceed in this way until the end of the sequence. Once the deprotected 
N-terminal amino acid, the resin washed 3 times with DCM and let it dry completely, 
then the cleavage. 
5. Resin cleavage 
After the removal of the Fmoc group from the last amino acid, wash 4 times with 
DCM and dry the resin under vacuum. Prepare the cocktails suitable for the cleavage 
and add it to the resin under magnetic stirring for 2 hours. After the cleavage, filter the 
suspension in a suitable solvent to precipitate the compound. Centrifuge the resulting 
suspension and remove the supernatant and repeated these steps twice to remove all 
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the scavenger used in the cleavage cocktail. The precipitate is, finally, solubilized and 
purified by preparative HPLC. 
6. Peptide purification  
The compounds are purified by preparative reverse phase HPLC, using an appropriate 
gradient of eluents A (H20/CH3CN/TFA, 97:3:0,1) and B (CH3CN/H2O/TFA, 
70:30:0,1 ) with a flow of 14 ml / min. 
The fractions containing the compound were concentrated in vacuo and acidified with 
a few drops of HCl (1M) to obtain the compound as the hydrochloride salt, instead of 
trifluoroacetate, and the mixture is finally lyophilized. 
  
¾ LQQCPF-RCS adducts preparation  
The peptide LQQCPF (final concentration 200 μM) was incubated with different aldehydes 
(HNE, HHE, or ACR; final concentration 2 mM) in 1 mM phosphate buffer (pH 7.4) for 24 h 
at 37 ° C.  
An aliquot of the synthesized adducts was reduced using NaBH4 (final concentration 5 mM) 
by a 60 min incubation at 37 °C and was subsequently desalted using a purification column 
(DSC-18 Supelco Discovery, 1 mL/100 mg Sigma-Aldrich Milan , Italy).  
 
¾ HPYFYAPELLFFAK-RCS adducts preparation  
The peptide HPYFYAPELLFFAK (final concentration 200 μM) was incubated with different 
aldehydes (HNE, CRO, NONE, or ACR; final concentration 2 mM) in 1 mM phosphate 
buffer (pH 7.4) for 24 h at 37 ° C. An alioquot of the synthesized adducts was reduced using 
NaBH4 (final concentration 5 mM) by a 60 min incubation at 37 °C and was subsequently 
desalted using a purification column (DSC-18 Supelco Discovery; 1 mL/100 mg Sigma-
Aldrich Milan , Italy). 
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¾  ESI-MS direct infusion analysis of the peptide-RCS adducts 
The LQQCPF and HPYFYAPELLFFAK-RCS adducts, reduced or not, were diluted (1:10, 
v/v) with a solution of MeOH: H2O: HCOOH (50:50:0.1, v/v/v) and analyzed by ESI-MS 
direct infusion approach.  
The analysis were performed using the mass spectrometer TSQ Quantum Ultra (Thermo 
Finnigan, Milan, Italy) using the following experimental conditions:    
• injection flow rate: 5μL/min   
• capillary temperature: 270 °C  
• ionization voltage: 5 kV  
• capillary voltage: 12.5 V  
• gas sheet (nitrogen) 0.5 L/min  
The MS/MS analysis were performed by applying an energy of collision of 20, 30, 40, and 50 
eV. 
 
¾ LC-ESI-MS precursor ion scan analysis of LQQCPF-RCS adducts  
The mixture containing LQQCPF native peptide and the reduced form of LQQCPF adducts 
with HNE, HHE, or ACR (25 μM each) was prepared in phosphate buffer 1 mM and diluted 
1:1 with MeOH:H2O:HCOOH (50:50:0.1 v/v/v). Aliquots of 50 μL was analyzed using HPLC 
system Surveyor LC system (ThermoQuest, Milan, Italy) equipped with a quaternary pump, 
detector UV/VIS photodiodes (PDA detector), autosampler, online degasser and thermostat; 
instrument control and data analysis were performed using the Xcalibur software (version 2.0, 
Thermo Electron Corporation).  
The elution of the peptides was obtained with a reversed phase column Agilent Zorbax SB-
C18 (150 mm x 4 mm id, particle Size 3.5 μM) (CPS analytical, Milan, Italy) protected by a 
guard column Agilent Zorbax RP; the mobile phase flow was maintained at 0.2 ml min-1, 
using a gradient eluition from 100% of phase A (H2O + 0.1% HCOOH) to 60% of phase B 
(CH3OH/H2O/HCOOH;90/10/0.1, v/v/v) in 80 minutes, followed by a period of 20 minutes of 
rebalancing; the pre-column and column temperature was maintained at 25°C. 
Samples were on line desalted and concentrated using a cartridge Opti-Lynx C18 (40 μM) 
(El-Chimie srl, Bresso, Milan, Italy) inserted into an injection valve Rheodyne 7010 
(Rheodyne, USA). ESI-MS analyses were performed using a mass spectrometer TSQ 
Quantum triple quadrupole Ultra (ThermoQuest, Milan, Italy), in positive ions scan, using the 
following experimental conditions:  
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• capillary temperature 270 °C; 
•  voltage of the spray 4,5 kV  
• capillary voltage of 12.5 V  
• nebulizer gas flow (nitrogen) 5 L/min 
Each sample was analyzed twice. First a full scan analysis in data-dependent scan mode was 
performed obtaining an isolation of the most abundant ions and their subsequent MS/MS 
fragmentation.  
Here below summarized the experimental conditions used are as follows:  
• repeat count 1  
• repetition duration 0.5 min  
• duration of the exclusion phase 2 min.  
The second analysis was performed in precursor ions scan mode, selecting the following 
product ions: m/z 242.1,  263.1 and 370.2 (collision energy 40 V).  
Both quadrupoles, Q1 and Q3, were set as follow:  
• resolution of mass of 1  
• scan time of 1 sec  
• Q1 the scan range m/z 300-1500. 
After the adducts were characterized by product ion scan analysis using the following 
experimental conditions:  
• Q1 resolution  0.7 m/z  
• scan time 1 s  
• collision energy 30 V  
• scan range 50-1500 m/z. 
 
¾ LC-ESI-MS precursor ion scan analysis of HPYFYAPELLFFAK-RCS adducts  
The same approach was used for the mixture containing the reduced form 
HPYFYAPELLFFAK native peptide and the HPYFYAPELLFFAK adducts with HNE, CRO, 
NONE, or ACR (25 μM each).  
The only difference was obviously in the product ions selected for the precursor ion scan 
analysis: m/z 512.13 and  964.60 (collision energy 40 V).  
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¾ Albumin-RCS adducts preparation  
Blood samples of six healthy volunteers, aged between 25 and 30 years, were collected in 
tubes containing sodium citrate as an anticonvulsivant. The plasma was separated by 
centrifugation at 2000 g for 20 min (4°C) and aliquots of 500 μl have been stored in liquid 
nitrogen until the analysis. The human serum albumin (HSA) was isolated using the Montage 
Albumin depleted Kit (Millipore, Milan, Italy) with 1 M NaCl as eluent phase (mean plasma 
HSA content 570 ± 34 μM). 
The HSA concentration was determined by spectrophotometry,  setting the length wave at 279 
nm (E 1% 1 cm = 5.31). Subsequently the samples were desalted using Microcon YM30 
centrifuge filter (Millipore, Milan, Italy), after a washing phase with distilled water.   
Then the samples were diluted in 20 mM phosphate buffer (PBS, pH 7.4) to obtain a final 
concentration of 20 μM. The aldehydes HNE, HHE or ACR were added to a final molar ratio 
of 1:10 HSA:RCS. 
After 120 min of incubation at 37°C, the samples were reduced with NaBH4 (final 
concentration 5 mM) at 37°C for 60 min, and were desalted with Microcon YM30 centrifuge 
filter, as described above. They have been stored in liquid nitrogen until the digestion step. 
 
¾ Samples proteolytic digestion  
The samples proteolytic digestion was performed according to the following scheme: 
1.  Dissolution in NH4HCO3 (50 mM) to a final concentration of 1mg/mL 
2. Addition to a 40 μL aliquot of 4 μL of NaBH4 (500 mM) and incubation at 37°C for 
45 min 
3.  Desalification phase using Microcon YM30 filter centrifuge (Millipore, Milan, Italy), 
after a washing phase with NH4HCO3 (50 mM).  
4. Addition of 4 μL of DTT (20 mM) as a reducing agent of the disulfide bridges and 
denaturation by one hour incubation at 60°C 
5. Alkylation of the cysteine thiol residues, by the addition of 16 μL of iodoacetamide 
(20 mM) and incubation for 1 h, at 37°C and protected from light 
6. Elimination of the exceeding iodoacetamide excess by further incubation for 1 h in the 
dark at 37°C after addition of 20 μL of DTT. 
7. Addition 20 μL of CaCl2 
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8. Trypsin or chimotripsin digestion at 37°C for 24 hours, using a enzyme/protein ratio 
equal to 1:20 (w/w). When both enzymes were necessary the samples were digested at 
37°C for 3 hours with trypsin and then overnight with chimotrypsin. 
9. Addition of TCA (40% w/v, 50 μL), stored on ice for 10 minutes, to a 200 μL samples 
aliquot and centrifugation at 18000 rpm for 10 minutes. 
Finally aliquots of 50 μL were injected into the LC-ESI-MS system (Surveyor LC system, 
ThermoFinnigan, Milan, Italy). The analysis by LC-ESI-MS were carried out in data-
dependent scan mode with precursor ion scan, as described above.  
 
 
¾ Tripsin-chimotripsin digested HSA-RCS adducts precursor ion scan analysis 
HSA isolated from serum plasma by affinity chromatography was incubated with different 
RCS (as describe in the paragraph “Albumin-RCS adducts preparation”) and digested with 
tripsin and chimotripsin (as described in paragraph “Samples proteolytic digestion”).   
The mixture containing HSA and HSA adducts with HNE, HHE, or ACR in reduced form (25 
μM each) was prepared in phosphate buffer 1 mM and diluted 1:1 with MeOH:H2O:HCOOH 
(50:50:0.1 v/v/v). Aliquots of 50 μL were analyzed using LC-ESI-MS precursor ion scan 
analysis as described in the paragraph “LC-ESI-MS precursor ion scan analysis of LQQCPF-
RCS adducts”.  
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 10.3 Cys 34 covalent modifications determination in 
patients undergoing hepatectomy surgery. 
In the present study plasma samples taken from three patients undergoing liver resection were 
analyzed. 
 During the surgery, it was possible to withdraw two different blood samples: 
1) Before anesthesia 
2) 10 min after de-clamping. 
Each sample was subjected to isolation of HSA and enzymatic digestion (as described in the 
paragraph “Albumin-RCS adducts preparation” and “Samples proteolytic digestion) and was 
analyzed according to the following scheme: 
1.   precursor ion scan analysis of LQQCPF-RCS adducts 
2.   characterization of the selected species by a product ion scan analysis 
3.   quantitative analysis of the identified adduct(s) by Multiple Reaction Monitoring (MRM)  
4.   MRM quantitative analysis of the LQQC(HNE)PF adduct  
5.   direct infusion of isolated HSA  
 
¾ Development of a method for quantitative analysis of the LQQC(HNE)PF adduct 
in Multiple Reaction Monitoring (MRM) 
The chromatographic separation was obtained with a reversed phase column Agilent Zorbax 
SB-C18 (150 mm x 4 mm id, particle Size 3.5 uM) (CPS analytical, Milan, Italy) protected by 
a guard column Agilent Zorbax RP; the phase flow of the mobile was maintained at 0.2 
mL/min with a linear gradient from 100% of phase A (0.1% HCOOH in H20) to 80% of 
phase B (CH3OH/H2O/HCOOH; 90/10/0.1, v/v/v) in 30 minutes, followed by a 5 minute 
period of rebalancing; the temperature of the system pre-column-column was maintained at 
25°C. 
The ESI-MS analysis was performed using a mass spectrometer TSQ Quantum triple 
quadrupole Ultra (ThermoQuest, Milan, Italy), using a positive ions scan mode, in the 
following experimental conditions: capillary temperature 270°C; voltage of the spray 3.2 kV; 
capillary voltage of 12.5 V; nebulizer gas flow (nitrogen) 5l/min. The optimization of the ESI 
instrumental parameters was performed by infusion of an analyte solution in mobile phase A 
(flow 10μL/min) through a T-connection, and maintaining the flow of the mobile phase at 0.2 
mL/min . The intensity of the ion [M + H]+ was optimized using the software Quantum Tune 
Master®. The quantitative analysis was performed in MRM mode (voltage multiplier 2:00 
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kV), by using the most stable and abundant product ions at optimized collision energy. The 
following [M + H]+ precursor ion → product ions transitions were used for the quantitative 
analysis: 
 
LQQC(HNE)PF m/z 893.4→ 262.0 + 372.0 (collision energy: 40 eV) 
LQQC(HNE)PF (D8) (IS) m/z 901.4 → 242.0 + 271.0 (collision energy: 40 eV) 
 
The instrumental parameters relating to these transitions were optimized as described below: 
collision (argon) gas pressure in cell Q2: 1.5 mbar; peak width at half height (FWMH): 0.70 
m/z for Q1 and Q3; scan range: 1 m/z, scan rate (dwell time): 0.2 s/scan. 
A calibration curve of the LQQC(HNE)PF adduct was then obtained using the following 
calibration solutions,  analyzed in duplicate in three replicates: 0.01 μM, 0.05 μM, 0.1 μM, 
0.5 μM, 1 μM, 5 μM, 10 μM; The calibration samples were diluted in a solution of internal 
standard (LQQC(HNE)PF (D8)) to a final concentration of 0.5 μM in 10 mM phosphate 
buffer, pH 7.4. 
The calibration line was obtained using the linear regression analysis of least squares (1/x2), 
using the peak area ratio of the analyte and of the IS versus the nominal concentration of the 
analyte.  
The limit of quantitation (LOQ) was determined as the concentration of the analyte which 
provides a peak whose height is equal to 9 times that of the background noise, while the limit 
of detection (LOD) as the concentration of the analyte which provides a peak whose height is 
equal to 3 times that of the background noise. 
 
¾ Direct infusion of isolated HSA 
The lyophilized albumin was solubilized in 200 μL of a denaturant mixture 
CH3CN/H2O/HCOOH (70/30/0.4, v/v/v) and the solution obtained was analyzed by direct 
infusion MS approach (injection speed 5 μL/min). 
Each sample was analyzed in two different mass range: m/z 900-1500 (Q = m/z 1) and m/z 
1400-1500 (Q = m/z 0.5) using the following instrumental conditions: positive ion mode; 
capillary temperature 270°C; spray voltage 3kV; capillary voltage 46 V; gas flow (nitrogen): 
0.5 L/min; acquisition time: 10 min. 
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11. Results 
11.1 Development of the method: ESI-MS characteristics 
of LQQCPF-RCS adducts 
The development of ESI-MS approach for the identification of Cys34 oxidative stress 
modifications involves several stages which may be summarized as follows:  
1. selection of proteolytic enzymes for the HSA digestion, aiming to generate a 4-6 
amino acids peptide (optimal for LC-MS/MS analysis) containing the Cys34 residue;  
2. identification of at least three product ions of the LQQCPF target peptide not 
containing the Cys 34 target residue. The precursor ions analysis of these fragments 
first leads to the selective identification of the molecular ions containing the three 
selected product ions linked to the LQQCPF peptide sequence. This approach allows 
to identify all the peptides containing the residue Cys 34, variously modified because 
the selected product ions do not contain the residual target. It is important also to 
highlight that this approach allows also the identification of the peptide having a 
differently modified Cys34 residue. Indeed, the identification is based on three 
selected product ions not including this target residue. 
3. characterization of the Cys34 modifications by MS/MS analysis in product ion scan 
mode. 
Considering the procedure described above, a particular digestion procedure was developed 
based on the use of both trypsin and chymotrypsin. This procedure allows us to obtain the 
LQQCPF peptide containing the residue Cys 34 and characterized by a number of amino acid 
suitable for the MS analysis.   
The development of the precursor ion scanning approach started with the selection of the most 
stable and abundant product ions not involving the target residue. These particular product 
ions belongs to the b and y series, before and after the Cys34 respectively. The selection 
involved a two steps approach. First, on the basis of the of theoretical fragmentation pattern a 
list of potential product ions was prepared namely: y1 (m/z 166.1), y2 (m/z 263.1), b2 (m/z 
242.1), b2-NH3 (m/z 225.1), b3 (m/z 370.2), b3-NH3 (m/z 353.2), RM (m/z 735.3) and finally, 
the ions immonio of Leu (m/z 86.0), Gln (m/z 101.1), Cys (m/z 76.0), Pro (m/z 70.1) and Phe 
(m/z 120.1).  
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Considering the theoretical fragmentation pattern above reported, in the second step, the most 
abundant and stable ions not containing the target residue Cys 34 were selected. A list of 
LQQCPF adducts was prepared, using α, β unsaturated aldehydes, with different side chains 
(HNE, HHE, ACR, CRO, NONE), dialdehydes (GO, MDA) and ketoaldehyde (MGO).  
The covalent products were identified and characterized by ESI-MS analysis and ESI-MS/MS 
analysis (direct infusion, in positive ion mode). As example, figure 18 shows the ESI-MS 
spectrum recorded in positive ion mode of LQQCPF incubated in the presence (panel A) or 
absence (panel B) of HHE;  
 
 
 
Figure 18 ESI-MS spectrum recorded in positive ion mode of LQQCPF incubated in the presence (panel A) or 
absence (panel B) of HHE 
The spectrum relative to the peptide incubated in the absence of HHE is characterized by the 
peptide molecular ion (m/z 735.4 [M+H]+), and by the corresponding sodium adduct m/z 
757.4 [M+Na]+) (Figure 18 A). The spectrum for the reaction mixture containing LQQCPF 
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incubated for 24h with HHE is characterized beside the [M+H]+ of the unmodified LQQCPF, 
also by the ion at m/z 849.5, attributed to the [M+H]+ of the Michael adduct with HHE 
(confirmed by analysis in MS/MS) (Figure 18 B). 
Table 11.1  summarizes the reaction products, obtained by the incubation of the LQQCPF 
peptide with the different selected aldehydes. 
 
 
 
 
 
Aldehyde LQQCPF adducts 
 Structure abbreviations [M+H]+ 
[M+H]+ 
(NaBH4)
ACR 
O
S
 
LQQC(ACR)PF 791.5 793.5 
CRO 
O
S
 
LQQC(CRO)PF 805.5 807.5 
HNE 
O
S
OH
 
LQQC(HNE)PF 891.6 893.6 
HHE 
O
S
OH
 
LQQC(HHE)PF 849.6 851.6 
NONE 
O
S
 
LQQC(NONE)PF 875.6 877.6 
MDA 
O
S
 
LQQC(MDA)PF 789.5 791.5 
GO S
OH
O
 
LQQC(GO)PF 793.9 795.9 
MGO 
S
OH
O
CH3
 
LQQC(MGO)PF 807.5 809.5 
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Table 11.1 
It can be observed that all the α,β-unsaturated aldehydes formed the corresponding Michael 
adducts, and ACR and CRO gave an additional cross-link with an amino propene structure, 
involving the terminal amino group of the peptide (data not shown). The reaction product 
between MDA and LQQCPF was attributed to a thio-propenal adduct through Michael 
adduction, followed by a dehydration step. GO and MGO formed the corresponding hemi-
thioacetal derivatives. We selected the diagnostic product ions for LC-ESI MS/MS analysis 
on the basis of the relative abundances at different collision energies (20, 30, 40, and 50 V) 
for native and modified LQQCPF.  
Figure 19 shows the isoplots of the relative intensities of these target product. At 20 V, the 
only detectable product ions were the retro-Michael fragments for LQQC(HNE)PF, 
LQQC(HHE)PF and LQQC(MGO)PF. 
At 30 V, the b2 and b3 ions were clearly detectable for all the covalent adducts, but the 
intensity of the y ions was negligible. At 40 V, b2, b3 and y2 were prominent for all the 
adducts, together with the immonium ion of the Leu residue (m/z 86.1). At 50 V, the b-ion 
series was conserved, while the y ions had almost completely disappeared.  
20V
30V
50V
40
 V
40
 V
 
Figure 19 shows the isoplots of the relative intensities of these target product. 
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We then did a similar study for the LQQCPF adducts reduced with NaBH4. This  procedure is 
required to stabilize the carbonylated peptide adducts and prevent them being lost during 
protein digestion (DDT for 60 min at 70 °C). 
ESI-MS and MS/MS direct infusion experiments confirmed, for each adduct, the quantitative 
reduction of the aldehyde to the alcohol group, as evidenced by the [M + H]+ values listed in 
Table 11.1. The fragmentation patterns at different collision energies were superimposable on 
those with non reduced LQQCPF adducts, except for the retro-Michael fragments which were 
not detectable at any collision energy. From these results we identified the collision energy 
that gives the most abundant, stable, and diagnostic fragment ions for LQQCPF covalently 
modified at the Cys34 residue, regardless of the adducted moiety. From the isoplots, we 
selected the following product ions at a collision energy of 40 V: y2 (m/z 263.1), b2 (m/z 
242.1) and b3 (m/z 370.2).  
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11.2 LC-ESI-MS analysis of the LQQCPF-RCS adducts  
The ESI-MS/MS was then coupled to LC to analyze a mixture of native and covalently 
modified LQQCPF, using the product ions listed above. The total ion current (TIC) showed 
several peaks eluting between 60 and 95 min (Figure 20 A). The ion current traces in 
precursor ion scanning mode were superimposable (Figure 20 B, C, D), and permitted the 
identification of all eight LQQCPF adducts in the mixture, as confirmed by the [M+H]+ of the 
precursor ions and the MS/MS spectra obtained in product-ion scan mode (data not shown).  
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Figure 20 LC-ESI-MS/MS analysis of a mixture of native and covalently modified LQQCPF, using the product 
ions listed above. Panel A shows the total ion current (TIC). Panel B, C, D show the ion current traces in 
precursor ion scanning mode  
 
Two additional peaks, not detectable in the precursor ion currents, were seen in the TIC trace 
at 66.5 min and 69.9 min, and assigned to the LQQCPF peptides cross-linked by ACR and 
CRO. Structure attribution was based on direct infusion experiments (data not shown), 
indicating that the cross-linked peptides had different fragmentation patterns from LQQCPF 
adducted to Cys34, not including the b2, b3 and y2 ions. 
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11.3 Application of the method: LC-MS/MS analysis of 
covalently modified HSA 
The method was applied to albumin incubated with HNE, HHE and ACR. Figure 21 A shows 
the TIC for digested native HSA, with several peaks corresponding to the different peptides. 
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Figure 21 Panel A TIC for digested native HAS. Panel B,C,D precursor-ion scan current recorded with the 
product ion set at m/z 242.1, 263.1 and 370.2 respectively. 
 
The precursor-ion scan current recorded with the product ion set at m/z 242.1 (Figure 21 B) 
contains not only a peak eluting at 49.3 min relative to the carboamidomethylated LQQCPF 
peptide [LQQC(CAM)PF] (precursor ion at m/z 792.5) but several other peaks too. The 
product ions at m/z 263.1 and 370.2 (Figure 21 panels C and D) gave similar results.  
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Figure 22 (panels A, B, C) shows the precursor-ion scan traces of HSA adducted by HNE and 
digested with trypsin/chymotryspin. In particular we have  isolated only two peaks since they 
were presented in all the three chromatograms and the molecular weight resulted the same in 
all the three recorded (m/z 792.5 and 893.6) attributed respectively to native LQQC(CAM)PF 
and LQQC(HNE)PF. 
This approach was then employed successfully to study the Cys34-covalent modifications of 
HSA incubated with the other two α,β-unsaturated aldehydes, HHE and ACR. The Michael 
adducts between LQQCPF and HHE (parent ion m/z 851.6) and ACR (parent ion m/z 793.5) 
(data not shown) were easily identified. 
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Figure 22 Panels A, B, C precursor-ion scan traces of HSA adducted by HNE and digested with 
trypsin/chymotryspin 
 
As a further validation of the approach, Figure. 23 reports the LC-MS chromatograms of a 
mixture containing digested HSA after incubation with HHE, HNE, ACR (5 μM final 
concentration for each analyte): all the peaks relative to LQQC(CAM)PF (peak a), 
LQQC(ACR)PF (peak b), LQQC(HHE)PF (peak c) and LQQC(HNE)PF (peak d) were easily 
identified and characterized. 
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Figure 23: LC-MS chromatograms of a mixture containing digested HSA after incubation with HHE, HNE, 
ACR (5 μM final concentration for each analyte) 
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11.4  Cys 34 covalent modifications determination in 
patients undergoing hepatectomy surgery. 
In the present study plasma samples taken from 3 patients undergoing hepatectomy surgery 
were analyzed at the following times:  
1) before anesthesia, 
 2) 10 min after de-clamping. 
HSA was isolated from plasma by affinity chromatography and digested with 
trypsin/chimotrypsin (see 10.2 Samples preparation and analytical methods). The peptide 
mixture was analyzed by LC-MS/MS in precursor ion scan mode ( see 11.3 Application of the 
method: LC-MS/MS analysis of covalently modified HSA). As example, Figure 24 shows the 
result of the analysis of sample 2 of subject 1 (10min after de-clamping), acquired by setting 
the product ions at m/z 242.1 (panel A), 263.1 (panel B), 370.2 (panel C).  
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Figure 24: Result of the analysis of sample 2 of subject 1 (10min after de-clamping), acquired by setting the 
product ions at m/z 242.1 (panel A), 263.1 (panel B), 370.2 (panel C). 
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All the three chromatograms are characterized by a main peak eluting at 20.98 minutes 
attributed to the peptide LQQC(CAM)PF (peak c). It is well evident that at least four other 
peaks can be detected: m/z 774.5 (a); m/z 543.65, (b ); m/z 793.4 (d); m/z 869.5 (e).  
Among these, the peaks a), b) and e) were discarded since their molecular weight resulted 
different in the three traces. 
Peak d) was instead isolated since it was presented in all the three chromatograms and the 
molecular weight resulted the same in all the three recorded (at m/z 793.4). 
The analysis of the samples related to subjects 2 and 3 showed the same peaks listed above. 
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11.5 Structural characterization: analysis by product ions 
scan mode 
An aliquot of the same sample was then analyzed using product ion scan mode, in order to 
confirm the peak at m/z 793.4 as a Cys 34 adduct peptide. 
The chromatogram obtained are reported in Figure 25: the MS/MS spectrum relative to the 
peak at m/z 793.4 was analyzed with the software Molecular Weight calculator (ver. 6.15) for 
the characterization of the fragment ions and permitted to assign the structure of 
LQQC(ACR)PF adduct.  
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Figure 25: MS/MS spectrum relative to the peak at m/z 793.4 was analyzed with the software Molecular Weight 
calculator (ver. 6.15) 
 
In particular, the following characteristic product ions were well evident in the MS/MS 
spectrum, as shown in Figure 25 B: y1 (m/z 166.1), y2 (m/z 263.1), b2 (m/z 242.1), b2-NH3 
(m/z 225.1), b3-NH3 (m/z 353.2), b3 (mz 370.2 ), and finally, the ion immonio of Gln (m/z 
101.1). 
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11.6 Quantitative analysis of the adduct LQQC(ACR)PF: 
analysis in MRM mode 
The previously described results led to the identification of the modified peptide 
LQQC(ACR)PF as the main biomarker of HSA oxidation. Therefore an MRM method for 
quantitative analysis of this adduct was developed, selecting the two most stable and abundant 
product ions (m/z 289.0 and m/z 531.1). Therefore, the following precursor ion → product 
ions transition was selected for the quantitative analysis: 
LQQC(ACR)PF m/z 793.4 → 289.0 + 531.1 (collision energy: 40 eV). 
As internal standard, the adduct LQQC(HNE)PF (D8) (final concentration of 0.5 μM) was 
used (being not available the corresponding deuterated adduct). The results obtained by the 
MRM analysis of the samples related to subject 1 and 2 are reported in Figure 26. After 10 
minutes of reperfusion (by de-clamping), the concentration of LQQC(ACR)PF increased by 3 
times (18.7 ± 7.1 nmol/mg albumin) compared to the concentration determined in pre-
anesthesia blood sample (5.9 ± 0.8 nmol/mg albumin). It is interesting to note that, in each 
case, the LQQC(ACR)PF adduct was well detectable also in samples taken before induction 
of ischemia-reperfusion injury, confirming the condition of oxidative stress of all the subjects 
analyzed. 
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Figure 26: results obtained by the MRM analysis of the samples related to subject 1 and 2 
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11.7 Development and application of a MRM method for 
the quantitative determination of the LQQC(HNE)PF 
adduct 
 
We then decided to set-up an MRM method for the quantitative determination also of the 
LQQC(HNE)PF taking account of the main role of HNE in oxidative stress. This choice could 
appear contrasting with the results obtained by precursor ion scan analysis, which couldn’t be 
able to detect any LQQC(HNE)PF adducts. However the product ion scan analysis is not a 
very sensible method, so it can detect only species at a high concentration. 
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Figure 27: MSMS spectra of the adduct LQQC(HNE)PF (m/z 893.4), after reduction with NaBH4, obtained by 
direct infusion analysis setting three different collision energies (20, 30 and 40 eV A,B,C respectively) 
 
Figure 27 shows the MS/MS spectra of the adduct LQQC(HNE)PF (m/z 893.4), after 
reduction with NaBH4, obtained by direct infusion analysis setting three different collision 
energies (20, 30 and 40 eV A,B,C respectively). It is well evident that increasing the collision 
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energy the most stable and abundant ions produced are characterized by a [M+H]+ at m/z 
262.0 (100% of relative abundance) and 372.0 (60% relative abundance). 
Similarly, the direct infusion of a solution of an equal concentration of the deuterated adduct 
LQQC(HNE)PF (D8) (m/z 901.4) (Figure 28) provided the ions at m/z 242.0 (100% relative 
abundance) and 271.0 (88% relative abundance) as the most abundant.  
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Figure 28 direct infusion of a solution of an equal concentration of the deuterated adduct LQQC(HNE)PF (D8) 
(m/z 901.4) 
 
Therefore the following precursor ion → product ions transitions for the quantitative analysis 
of the adduct LQQC(HNE)PF were used: 
LQQC (HNE) PF m / z 893.4 → 262.0 + 372.0 (collision energy: 40 eV) 
LQQC (HNE) PF (D8) (IS) m / z 901.4 → 242.0 + 271.0 (collision energy: 40 eV) 
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Figure 29 is shown the LC-MS/MS profile of a sample of blank human plasma, added with 
mixture of analyte (Figure 29 A) and internal standard (Figure 29  B) to a final concentration 
0.5 μM (LOQ); the analytes elute at about 24 min in a range of 0.6-0.8 min. 
The calibration curve was linear over the entire range of calibration (0.01 μM - 10 μM), with 
a correlation coefficient r2 greater than 0.999. The relative equation is the following: 
y = 1.345 (± 0067) x - 0096 (± 0.0008). 
 
18 19 20 21 22 23 24 25 26 27 28 29
Time (min)
0
50
100
R
el
at
iv
e 
A
bu
nd
an
ce
24.03 901.400@cid35.00
[241.000-243.000,
270.000-272.000] 
LQQC(HNE)PF-(D8)
0
50
100
24.07
893.400@cid30.00
[262.000-264.000,
371.000-373.000] 
LQQC(HNE)PF
A)
B)
 
Figure 29:  shown the LC-MS/MS profile of blank human plasma, added with mixture of analyte (A) and 
internal standard ( B) to a final concentration 0.5 μM 
 
The LOD, defined as a signal/noise ratio equal to 3, was 0.005 mM, while the LOQ  defined 
as a signal/noise ratio equal to 9, was 0.01 μM. 
The method was then applied for the quantitative analysis of the samples of the three subjects 
underwent hepatotectomy. In all plasma samples, the levels of LQQC(HNE)PF adduct were 
below the LOD (data not shown). 
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11.8 Analysis of native HSA by direct infusion 
 
¾ Determination of cysteinylated HSA by ESI-MS direct infusion 
 
The cysteinylated HSA is considered an extracellular potential biomarker of oxidative stress. 
This adduct is formed by reaction between the thiol group and oxidative species leading to  
the formation of the corresponding sulfenic acid which, in a second step, reacts with cysteine 
forming the mixed disulfide. 
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Figure 30: Panel A shows the ESI-MS spectrum relative to HSA serum acquired in positive ion. Panel B) shows 
the ESI-MS spectrum in positive ion mode of HSA isolated from human serum, characterized by three series of 
multicharged ions related to three species.  
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Therefore, a MS methodology was developed in direct infusion in order to determine the 
relative percentage of cysteinylated HSA.  
Figure 30 (panel A) shows the ESI-MS spectrum relative to HSA serum (scan range m/z 900-
1500), acquired in positive ion. The spectrum presents a series of multicharged ions in the 
range between m/z 1073 and m/z 1478 (addition of 62-45 protons). To further improve the 
resolution we then analyzed the sample reducing the scan range (m/z 1410-1500) and 
acquiring the MS spectrum for 10 min. The resolution was equal to m/z 0.5. 
Figure 30 (panel B) shows the ESI-MS spectrum in positive ion mode of HSA isolated from 
human serum, characterized by three series of multicharged ions related to three species. The 
first series, resulted the most abundant, is characterized by three ions (m/z 1414.8, 1445.5 and 
1477.2) attributed to multicharged ions of HSA by addition of 47, 46 and 45 protons 
(compound A). The second series is characterized by the three ions (m/z 1417.3, 1448.2, 
1480.2 compound B) and the third at m/z 1418.2, 1449.0, 1481.2 (compound C), with a 
relative abundance of 30-35% compared to native HAS. 
The de-convoluted compound A spectrum is characterized by the molecular weight of 66446 
Da, which is similar to the HSA theoretical value 66429 (μM = +17 Da), obtained on the 
basis of the amino acid sequence (SwissProt: registration number P02768). The molecular 
weight of the compounds B and C were respectively of 66566 and 66610 Da, corresponding 
to a mass increase equal to 120 and 164 Da. On the basis of the mass values obtained, the 
compounds B and C were attributed to the cysteinylated (theoretical mass increment of 119 
Da) and glycated form (162 Da) of HSA. The assignment was confirmed treating HSA with 
the reducing agent NaBH4. In such conditions the disappearance of the signal related to 
compound B was observed, due to the reduction of the disulfide bond, as expected, the 
glycated form (compound C) resulted unmodified (Fig. 22, panel C). The percentage of the 
cysteinylated form can be determined by calculating the percentage ratio between the 
intensity of the cysteinylated form in respect to the sum of the different forms of albumin. 
Under physiological conditions the cysteinylated form, as well as glycated, is between 15 and 
20%. 
¾ Determination of cysteinylated HSA in patients undergoing hepatectomy surgery 
 
HSA isolated from plasma samples taken from the three patients undergoing the hepatic 
resection was analyzed by direct infusion in order to measure the percentage of HSA 
cysteinylated form.  
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Figure 31: The spectra analysis indicates that the percentage of HSA cysteinylated form before anesthesia 
(sample 1) 
 
The results related to sample 1 and 2 of subject 1 are reported in figure 31. The spectra 
analysis indicates that the percentage of HSA cysteinylated form before anesthesia (sample 1) 
was about 51% which is higher than the average found in the healthy subject. 
The spectrum analysis relative to the sample taken 10 minutes after declamping (sample 2) 
shows a significant reduction of the percentage of the cysteinylated form (34%). The observed 
trend is completely similar for the other two patients (data not shown). 
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11.9 ESI-MS analyses of the HPYFYAPELLFFAK-RCS 
adducts: development of the method 
The development of ESI-MS approach for the identification of His 146 oxidative stress  
induced modifications was performed following the same procedure discussed for LQQCPF 
adducts.  
The digestion of HSA with tripsyn or with tripsyn/chimotrypsin led to two different peptides 
containing the target residue. In particular by tripsyn digestion a peptide characterized by 14 
amino acids was obtained, with the following sequence HPYFYAPELLFFAK; on the other 
hand by tripsyn/chimotrypsin digestion we obtained a 3 amino acids peptide (HPY).  
Starting from the first obtained peptide, we applied the same procedure above described, 
LQQCPF peptide, by selecting the most suitable product ions to be used for precursor ion 
scan analysis. 
In this particular case, only the fragments belonging to the y series could be chosen as 
described in the sequence below reported. 
 
 
 
Among the y series ions, we then selected the most stable and abundant fragment ions, as 
performed for LQQCPF peptide. Therefore, the adducts between the HPYFYAPELLFFAK 
peptide and a list of α-β unsaturated aldehydes (HNE, HHE, ACR, CRO, NONE) were 
synthesized.  
These adducts were then identified and characterized by ESI-MS and ESI-MS/MS analysis 
(direct infusion, in positive ion mode). As example, Figure 32 shows the ESI-MS spectrum  
of HPYFYAPELLFFAK peptide, incubated in the presence (24h incubation) or absence of 
HNE, acquired in positive ion mode. 
 
Results 
      139 
 
 
Figure 32: ESI-MS spectrum of HPYFYAPELLFFAK peptide, incubated in the presence (24h incubation) or 
absence of HNE, acquired in positive ion mode. Spectrum A is relative to the peptide incubated in the absence of 
HNE. The spectrum B corresponds to the [M+2H]2+ adduct with HNE 
 
The spectrum A, relative to the peptide incubated in the absence of HNE, is characterized 
only by the molecular ion of the peptide (m/z 872.1 [M+2H]2+). In the spectrum B, the signal 
corresponding to the [M+2H]2+ adduct with HNE (m/z 950.74) is well detectable, besides the 
one related to the [M+2H]2+ of the native peptide (m/z 871.82). 
Table 11.2 summarizes the products ions, obtained by the incubation of the 
HPYFYAPELLFFAK peptide with HNE, HHE, ACR, CRO, NONE, all identified by mass 
spectrometric analysis.  
 
RCS Structure [M+H]+ 
HNE R
N
OH
 
1901.94 
ACR 
 
181.92 
CRO 
 
1815.94 
NONE 
 
1886.12 
 
Table 11.2 
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These adducts were then analyzed by MS/MS analysis using different collision energies (20, 
30, 40 and 50V). Best results were obtained by choosing 40 eV as collision energy (data not 
shown). 
 In particular, y4 and y8 product ions resulted to be the most abundant fragment ions common 
to all the analyzed adducts as reported in figure 33, and for this reason they were choosen for 
the precursor ion scan method.  (see paragraph 11.10) 
 
y1 y2 y3 y4 y5 y6 y7 y8 y9 y10 y11
0
100
200 native
HNE
ACR
CRO
NONE
512.3 m/z
964.6 m/z
@40V
 
Figure 33: Best results obtained by choosing 40 eV as collision energy 
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11.10 LC-ESI-MS analysis of HPYFYAPELLFFAK-RCS 
adducts  
 
The HPYFYAPELLFFAK native peptide and HNE adduct were then analyzed using LC-ESI-
MS analysis in precursor ions scan mode. Figure 34 shows the obtained total ion current 
(TIC) characterized by two peaks eluting between 19.5 and 21 min (Figure 34 A). The other 
panels show the precursor ion traces obtained by setting the product ions to m/z 512.29.(B) 
and m/z 964.55 (C), as previously reported.  
The two peaks are characterized by a molecular weights corresponding to the native peptide 
and to HNE adduct respectively.  
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Figure 34 Panel A shows the TIC. Panels B and C show the precursor ion traces obtained setting the selected 
product ions 
 
The structures of the two peaks were then confirmed by the MS/MS data obtained by a 
product-ion scan analysis as reported in the following chapter. 
Results 
      142 
 
11.11 Structural characterization: analysis by product ions 
scan mode 
An aliquot of the same sample was then analyzed by product ion scan mode, in order to 
confirm the nature of the peak at m/z 950.7 as an adduct peptide of His 146. 
The chromatogram obtained is reported in figure 35 (A).  
 
19.0 19.5 20.0 20.5 21.0 21.5 22.0 22.5 23.0 23.5
Time (min)
0
10
20
30
40
50
60
70
80
90
100
R
el
at
iv
e
A
bu
nd
an
ce
Product Ion Scan chromatogram @ 40 eV
90
268.02
100 200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500
m/z
0
10
20
30
40
50
60
70
80
100
R
el
at
iv
e 
A
bu
nd
an
ce
393.12
217.95 365.06119.87
512.13
340.02 1163.63 1276.88582.11408.04
964.41
695.24 1389.82866.30 1490.97
y8
y4
SIC trace m/z 950.97
A)
B)
 
Figure 35 Panel A show the analyzed by product ion scan mode. Panel B show the MS/MS spectrum 
 
The analysis of the MS/MS spectrum (figure 35 B) permitted us to assign the structure of the 
H(HNE)PYFYAPELLFFAK adduct because all the product ions were well evident: in 
particular the most abundant y4 (m/z 512.3) and y8 (m/z 964.41.1).  
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11.12 LC-MS/MS analysis of covalently modified HSA. 
  
The method was then applied for the identification of the covalent HSA modifications after 
incubation with HNE. In particular, carbonylated HSA was subjected to enzymatic digestion 
with trypsin and then stabilized by reduction with NaBH4. 
As example, Figure 36 reports the LC-ESI-MS/MS traces (mass range m/z 100-1500), 
relative to the precursor ions scan analysis of the digested native HAS. In particular, panel A 
reports the TIC while panels B and C the ion traces obtained selecting the ions at m/z 512.29 
and m/z 964.55 as product ions. 
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Figure 36 LC-ESI-MS/MS traces (mass range m/z 100-1500), relative to the precursor ions scan analysis of the 
digested native HAS 
 
In all the three reported spectra the peak eluting at 20 min is well evident, related to the 
HPYFYAPELLFFAK native peptide.  
The expected H(HNE)PYFYAPELLFFAK adduct at 21 minutes resulted undetectable. 
For this reason the same sample was subjected to high-resolution, high mass accuracy mass 
spectrometry analysis using a LTQ-Orbitrap mass spectrometer. 
In details a full scan analysis in data-dependent scan mode followed by data analysis with the 
SEQUEST algorithm was performed. The results obtained were able to explain the absence of 
any signals related to H(HNE)PYFYAPELLFFAK adducts with the presence of different 
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missed cleavages. Indeed, the SEQUEST algorithm compares the data obtained from LTQ-
Orbitrap with the primary sequence of HSA and with all the possible covalent modifications 
induced by HNE, resulting in the identification of post-traslational modifications. 
In particular the following missed cleavages were identified: 
1. one missed cleavage peptides: 
RHPYFYAPELLFFAK 
HPYFYAPELLFFAKR 
2. two missed cleavages peptide 
HPYFYAPELLFFAKRYK 
3. three missed cleavages peptide 
RHPYFYAPELLFFAKRYK 
  
To overcome the synthesis of all the possible peptides and of the corresponding RCS-adducts 
for a new study in precursor ion mode, we decided to carry out an alternative mass 
spectrometric approach, based on the direct analysis of trypsin/chymotrypsin HNE-HSA 
digested peptides in product ion scan mode, in order to characterize, on the basis of the 
predicted [M+H]+ ions, all the formed adducts. In particular, considering the possible 
presence of different missed cleavages, we expected to obtain three different [M+H]+: 
• HPY (m/z = 574.23) 
• RHPY (m/z = 730.33) 
• HPYF (m/z = 721.30) 
As example, Figure 37 shows the LC-ESI-MS/MS chromatogram (mass range m / z 100-
1500), obtained by product ions scan mode analysis of the digested native HSA. 
Panel A reports the select ion chromatogram trace at 721.35 [H(HNE)PYF+H]+: a single peak 
eluting at 88 min is well evident. 
Panel B shows the MS/MS spectrum related to this peak confirming the expected molecular 
weight. 
The SIC traces related to the other two possible peptide resulted undetectable. 
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Figure 37: LC-ESI-MS/MS chromatogram (mass range m / z 100-1500), obtained by product ions scan mode 
analysis of the digested native HSA. 
 
The results indicated the formation of one adduct only, H(HNE)PYF, but without a significant 
fragmentation of the corresponding [M+H]+, even at high collision energy (40eV). 
Hence considering all these results, we have finally considered as alternative approach the 
application of a new HSA digestion strategy, based on the use of chimotripsin only. In silico 
studies indicated EIARRH*PY as a new tag peptide containing the target residue His 146 in 
the middle of the peptide, like Cys 34 in the LQQC*PF peptide. The specific position of His 
146 within the new tag peptide (that reasonably will reduce the risk of missed cleavages), and 
the lenght of the peptide (suitable to obtain significant MS/MS data for structure confirmation 
of RCS-adducts), can be considered as optimal characteristics to start a new MS strategy 
involving His 146 as a carbonyl adduction site on HSA.  
Thus, HSA was isolated from human plasma by affinity chromatography, reduced with 
NaBH4 and digested with chimotrypsin only, in order to obtain the expected peptide. The 
peptide mixture was analyzed by LTQ-Orbitrap in data-dependent scan mode and the data 
obtained were further analyzed by the SEQUEST algorithm.  
As example, Figure 38 shows LC-ESI-MS/MS chromatograms (mass range m / z 100-1500), 
obtained in data-dependent scan mode of the HSA digested native (panel A). 
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Panel B reports the select ion chromatogram trace at 521.28, indicating the presence of the 
expected tag peptide.  
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Figure 38: LC-ESI-MS/MS chromatograms (mass range m / z 100-1500), obtained in data-dependent scan mode 
of the HSA digested native 
 
The SEQUEST algorithm compares the obtained data with the primary sequence of the HSA. 
The results (Table 11.3) of the analysis confirmed the formation of the expected peptide (see 
the last two lines of the table). 
In this way we created the bases for the future studies on the EIARRH*PY peptide, in order to 
identify any covalent modifications of His146 induced by RCS. 
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Time(s) Peptide [M+H]+ 
10.84 Y.AEAKDVF.L 779.39340 
10.76 Y.AEAKDVF.L 779.39340 
9.25 - 9.31 F.AEVSKL.V 646.37702 
16.32 F.AKTC*VADESAENC*DKSLHTLF.G 2396.08569 
16.21 F.AKTC*VADESAENC*DKSLHTLF.G 2396.08569 
16.13 - 16.20 F.AKTC*VADESAENC*DKSLHTLF.G 2396.08569 
16.87 - 16.92 Y.AKVFDEF.K 855.42470 
24.27 Y.AKVFDEFKPL.V 1193.65649 
23.66 - 23.73 Y.AKVFDEFKPL.V 1193.65649 
24.42 Y.AKVFDEFKPL.V 1193.65649 
24.34 Y.AKVFDEFKPL.V 1193.65649 
24.35 Y.AKVFDEFKPL.V 1193.65649 
23.74 - 23.81 Y.AKVFDEFKPL.V 1193.65649 
31.28 - 31.36 Y.AKVFDEFKPLVEEPQNL.I 2003.04842 
31.36 - 31.43 Y.AKVFDEFKPLVEEPQNL.I 2003.04842 
12.50 Y.ARRHPDYSVVL.L 1312.71204 
12.50 Y.ARRHPDYSVVL.L 1312.71204 
12.60 Y.ARRHPDYSVVL.L 1312.71204 
16.45 - 16.50 Y.ARRHPDYSVVLL.L 1425.79611 
8.94 -.DAHKSEVAHRF.K 1296.64436 
9.45 -.DAHKSEVAHRF.K 1296.64436 
8.89 -.DAHKSEVAHRF.K 1296.64436 
13.42 F.DEFKPL.V 748.38758 
13.34 F.DEFKPL.V 748.38758 
28.64 F.DEFKPLVEEPQNL.I 1557.77951 
28.75 F.DEFKPLVEEPQNL.I 1557.77951 
8.58 - 8.65 Y.EIARRHPY.F 1041.55884 
8.66 - 8.71 Y.EIARRHPY.F 1041.55884 
 
Table 11.3 
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12. Discussion 
The protein carbonylation is an important mechanism of oxidative damage mediated by the 
formation of carbonyl species (RCS) generated by oxidation of sugars and lipids.  
RCS and the related adducts with proteins (so called, carbonylated proteins) are widely used 
as biomarkers of lipid peroxidation and, in general, of oxidative stress76.  
Moreover, a strict correlation between carbonyl stress and certain human diseases is well 
established. The accumulation of carbonylated proteins is commonly recognized as a common 
feature of aging in tissue proteins, and the levels of these compounds resulted increased either 
systemically or locally in a broad range of diseases, including diabetes, atherosclerosis and 
kidney, hepatic, and neurodegenerative diseases203-206. Whether carbonylation represents a 
cause or an effect is still to be fully clarified, although, for some diseases, several convincing 
evidences support a pathogenic role, such as in the case of diabetic-related diseases207, age-
dependent tissue dysfunction, neurodegenerative diseases208, and atherosclerosis148. 
Consequently, protein carbonylation is a  predictive biomarker of oxidative damage and 
represents a biological target for drug discovery209, 210. 
Therefore, the need of suitable analytical methods not only for the diagnosis but also for 
better understanding the mechanisms involved in the carbonylation damage is well evident. 
Nowadays, the carbonylation damage is mainly measured by immunological techniques using 
mono-and poly-clonal antibodies specific for carbonylated proteins. This approach has been 
widely used to give an index of systemic and tissue carbonylation, but it cannot identify and 
characterize the sites of the reaction. 
 The advent of proteomics and hence separation of proteins by 2D- analysis  followed by 
immunoblotting has given the possibility to identify the proteins most involved in the 
carbonylation process, providing an in-depth analysis of the mechanisms involved in protein-
dependent oxidative process. 
However, an analytical strategy to map a wide range of known and unknown RCS is needed 
to understand how they are involved in different oxidative-based disorders, and to formulate 
an appropriate pharmacological strategy, for example by designing carbonylation damage 
inhibitors. 
The technique here proposed was therefore designed to establish a specific and sensitive 
analytical approach to identify and characterize all the oxidative modifications (even not 
carbonyl-derived) of an endogenous target protein (human serum albumin), without requiring 
external standards.  
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Conventional proteomic approaches indicate albumin as the main target of carbonylation in 
serum188, 189. Albumin can be carbonylated by several mechanisms, such as direct oxidative 
reactions sustained by reactive oxygen species (ROS) or covalent adduction induced by 
electrophilic compounds such as HNE and ACR64. Proteomics approaches have led to the 
identification of the protein/s showing high sensitivity to oxidation/carbonylation, and among 
them HSA was found to be the main target in the circulation188-190. 
The high reactivity of HSA towards electrophilic RCS185, 211 could be explained both by the 
elevated HSA plasma concentration (∼ 0.6mM) and to several accessible nucleophilic 
residues, mainly Cys 34, followed by His 146 and Lys 199185, 191. Among these sites, Cys 34 
resulted the most reactive site, able to react with alfa, beta unsaturated aldehydes better than 
GSH, followed by His 146. 
Thus, considering HSA Cys 34 as the main targets of carbonylation in human serum, the MS 
strategy proposed here seeks to identify covalent modifications induced by 
oxidative/carbonylation damage. 
Cys 34 is a sensitive residue for various post-translational modifications besides 
carbonylation, including S-nitrosylation, disulfide formation and oxidation to sulfenic, 
sulfinic and sulfonic derivatives. These have all attracted interest because of their correlations 
with physiopathological conditions such as intrauterine growth restriction and kidney disease 
(Cys 34 cysteinylation and homocysteinylation212, 213), glomerulosclerosis (Cys 34 
sulphonation 214) and oxidative stress (Cys 34 oxidation215). A MS method to identify and 
characterize all the Cys 34 covalent modifications would be valuable not only for studying 
RCS-modified albumin, but also to check the oxidative state of Cys34 as a marker of 
oxidative damage. 
In order to obtain a rapid identification and characterization of Cys34 covalent modifications, 
a MS strategy based on the precursor-ion scanning technique was used. By the application of 
this technique, it has been possible to selectively identify the molecular ion of all the tryptic 
peptides containing the Cys34 residue in native or modified form. This type of MS approach 
gives rapid confirmation of targeted compounds, or non-targeted detection of compounds with 
a common moiety, and it has been widely used in drug discovery and development216 and in 
vitro/in vivo drug-metabolism studies131. 
The technique was initially validated in several in vitro models and provided very good 
results in terms of selectivity. In particular, the Cys-34 adducts were easily identified by 
incubation of HSA with different reactive carbonyl species. Once setup, the method was then 
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applied for the identification of the main HSA-Cys 34 oxidative modifications isolated from 
patients undergoing liver resection.  
This type of surgery involves a blood clamping step followed by a reperfusion phase. This 
procedure is known to be strictly correlated with a significant oxidative stress because of the 
activation of xanthine oxidase and of the accumulation of hypoxanthine during the ischemic 
phase, followed by an oxygen intake during the reperfusion step. The co-presence of these 
substrates/enzymes causes the superoxide anion formation, which represents a well-known  
precursor of hydroxyl radicals, species mainly responsible for the oxidative process. We can 
therefore assist that the liver resection and the condition of induced ischemia/reperfusion 
represent an in vivo model of oxidative stress. 
The results obtained by precursor ion scan analysis led to the identification, as the only 
oxidative modification, of the Michael adduct between Acrolein and Cys 34 in all three 
subjects who underwent the liver resection. Acrolein is an  α,β-unsaturated aldehydes 
generated by lipid peroxidation and characterized by a very high electrophilicity.  
On the basis of this qualitative evidence, a MRM (multiple reaction monitoring) method was 
developed, in order to perform a quantitative analysis of the LQQC(ACR)PF adduct.  
The MRM analysis was able to determine the presence of this adduct also before the surgery, 
an evidence congruent with the medical case and the hepatic dysfunction affecting these 
patients, and so with the correlated oxidative stress. 
The LQQC(ACR)PF adduct was also found to be significantly increased after the reperfusion 
step, confirming that this adduct can be considered as a sensible biomarker of the oxidative 
process. 
In addition, the ESI/MS analysis of native albumin by direct infusion approach (see paragraph 
11.8) showed the disulfide formation of Cys 34 by cysteinylation, with a 50% increased level 
in all three subjects before the anesthesia, a significantly higher value compared to the one 
found in healthy subjects. This results confirm that the oxidative stress condition is already 
established before the surgery, as indicated by the determination of the LQQC(ACR)PF 
adduct.  
Unexpectedly, the level found at the end of the reperfusion injury resulted slightly decreased. 
Several hypotheses could be postulated to explain these data, including the reduced 
availability of extracellular Cys most likely involved in the oxidative detoxification processes. 
In parallel, MS studies performed in our laboratory using the same approach, we confirm that 
Cys 34 undergoes cysteinylation also in another in vivo model of oxidative stress, such as 
uremic subjects (data not shown). This result confirmed that in some pathological conditions 
Discussion 
 
      151 
 
the target site Cys 34 could be blocked by the disulfide bond, thus  limiting its ability to react 
with RCS. 
Hence, Cys 34-adducts couldn’t always be useful as carbonylation biomarkers. Therefore, 
during my PhD study, I focused my attention on another HSA nucleophilic site (His-146), 
previously recognized as a potential oxidation/carbonylation target185. 
Digesting HSA with tripsin or tripsin+chimotripsin, two different peptides containing His-146 
have been obtained: H*PYFYAPELLFFAK and H*PY, respectively.  
Anyway, analysis of tripsin or tripsin+chimotripsin digested HNE-HSA adduct did not lead to 
identification of any covalent modifications on His 146. 
Using an high-resolution, high mass accuracy mass spectrometer (LTQ-Orbitrap), performing 
a full scan analysis in data-dependent mode followed by data analysis with the SEQUEST 
algorithm, it was possible to explain that the absence of any signals relative to RCS-
H*PYFYAPELLFFAK adducts was due to different missed cleavages. 
The analyses relative to the H*PY peptide indicated the formation of one adduct only, 
H(HNE)PYF, but no significant fragmentation of the corresponding [M+H]+ was observed in 
MS/MS experiments, even working at high collision energy (40eV). Maybe the reason could 
be that the peptide is too short for an optimal fragmentation. 
Taking account of these observations, we have considered as alternative approach the 
application of a new HSA digestion strategy, based on the use of chimotripsin only. In silico 
studies indicated the EIARRH*PY peptide as a new tag containing the target residue His 146 
in the middle, exactly like Cys-34 in the LQQC*PF peptide, previously analyzed with 
satisfactory results. This new peptide has also the appropriate length to be analyzed by HPLC-
MS/MS. Hence, the EIARRH*PY peptide seemed to possess the optimal characteristics to 
start a new MS strategy involving His-146 as a carbonyl adduction site on HSA. 
Thus, HSA was isolated from human plasma by affinity chromatography, reduced with 
NaBH4 and digested with chimotripsin only in order to obtain the expected peptide. The 
peptide mixture was analyzed by LTQ-Orbitrap in data dependent scan mode and afterwards 
by the SEQUEST algorithm, comparing the obtained data with the primary sequence of the 
protein. The results of the analysis confirmed the formation of the expected peptide. 
In this way we created the bases for the future studies on the EIARRH*PY peptide, in order to 
identify any covalent modifications of His146 induced by RCS. 
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13 Conclusions 
In  this second part of my PhD thesis, it has been developed a mass spectrometry method for 
the rapid and selective identification and characterization of the oxidative modification of 
proteins. 
Considering the studies performed to investigate HSA- Cys 34 covalent modifications, the 
application of the method to plasma samples taken from patients undergoing liver resection 
has made possible to identify Acrolein as the main aldehyde generated by oxidative stress 
condition. 
Considering the analysis performed to study HSA- His 146, we performed a new HSA 
proteolytic digestion strategy based on the use of chimotrypsin only. This results can be 
considered the bases for the future studies on the EIARRHPY peptide, in order to identify any 
covalent modifications of His146 induced by RCS. 
Such informations provide an explanation necessary to understand the mechanisms 
underlying oxidative stress, induced by a condition of ischemia / reperfusion, and also to 
select biologically active compounds targeted to the detoxification of such cytotoxic oxidation 
products. 
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